The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM NPORT-P
Monthly Portfolio Investments Report

NPORT-P: Filer Information

Confidential
Filer CIK
0001314966
Filer CCC
********
Filer Investment Company Type
Is this a LIVE or TEST Filing? LIVE TEST
Would you like a Return Copy?
Is this an electronic copy of an official filing submitted in paper format?

Submission Contact Information

Name
Phone
E-Mail Address

Notification Information

Notify via Filing Website only?
Notification E-mail Address
Series ID
Class (Contract) ID

NPORT-P: Part A: General Information

Item A.1. Information about the Registrant.

a. Name of Registrant
BlackRock Health Sciences Trust
b. Investment Company Act file number for Registrant: (e.g., 811-______)
811-21702
c. CIK number of Registrant
0001314966
d. LEI of Registrant
4UL0KI4EPYFKMUU31I34
e. Address and telephone number of Registrant:
i. Street Address 1
100 BELLEVUE PARKWAY
ii. Street Address 2
iii. City
WILMINGTON
iv. State, if applicable
v. Foreign country, if applicable
vi. Zip / Postal Code
19809
vii. Telephone number
800-441-7762

Item A.2. Information about the Series.

a. Name of Series.
BlackRock Health Sciences Trust
b. EDGAR series identifier (if any).
c. LEI of Series.
4UL0KI4EPYFKMUU31I34

Item A.3. Reporting period.

a. Date of fiscal year-end.
2023-12-31
b. Date as of which information is reported.
2023-03-31

Item A.4. Final filing

a. Does the Fund anticipate that this will be its final filing on Form N PORT? Yes No

NPORT-P: Part B: Information About the Fund

Report the following information for the Fund and its consolidated subsidiaries.

Item B.1. Assets and liabilities. Report amounts in U.S. dollars.

a. Total assets, including assets attributable to miscellaneous securities reported in Part D.
607466481.00
b. Total liabilities.
23005687.39
c. Net assets.
584460793.61

Item B.2. Certain assets and liabilities. Report amounts in U.S. dollars.

a. Assets attributable to miscellaneous securities reported in Part D.
0.00000000
b. Assets invested in a Controlled Foreign Corporation for the purpose of investing in certain types of instruments such as, but not limited to, commodities.
0.00000000
c. Borrowings attributable to amounts payable for notes payable, bonds, and similar debt, as reported pursuant to rule 6-04(13)(a) of Regulation S-X [17 CFR 210.6-04(13)(a)].
Amounts payable within one year.
Banks or other financial institutions for borrowings.
0.00000000
Controlled companies.
0.00000000
Other affiliates.
0.00000000
Others.
0.00000000
Amounts payable after one year.
Banks or other financial institutions for borrowings.
0.00000000
Controlled companies.
0.00000000
Other affiliates.
0.00000000
Others.
0.00000000
d. Payables for investments purchased either (i) on a delayed delivery, when-issued, or other firm commitment basis, or (ii) on a standby commitment basis.
(i) On a delayed delivery, when-issued, or other firm commitment basis:
0.00000000
(ii) On a standby commitment basis:
0.00000000
e. Liquidation preference of outstanding preferred stock issued by the Fund.
0.00000000
f. Cash and cash equivalents not reported in Parts C and D.
163396.94000000

Item B.3. Portfolio level risk metrics.

If the average value of the Fund's debt securities positions for the previous three months, in the aggregate, exceeds 25% or more of the Fund's net asset value, provide:
a. Interest Rate Risk (DV01). For each currency for which the Fund had a value of 1% or more of the Fund’s net asset value, provide the change in value of the portfolio resulting from a 1 basis point change in interest rates, for each of the following maturities: 3 month, 1 year, 5 years, 10 years, and 30 years.
b. Interest Rate Risk (DV100). For each currency for which the Fund had a value of 1% or more of the Fund’s net asset value, provide the change in value of the portfolio resulting from a 100 basis point change in interest rates, for each of the following maturities: 3 month, 1 year, 5 years, 10 years, and 30 years.

Currency Metric RecordISO Currency code3 month1 year5 years10 years30 years

c. Credit Spread Risk (SDV01, CR01 or CS01). Provide the change in value of the portfolio resulting from a 1 basis point change in credit spreads where the shift is applied to the option adjusted spread, aggregated by investment grade and non-investment grade exposures, for each of the following maturities: 3 month, 1 year, 5 years, 10 years, and 30 years.

Credit Spread Risk3 month1 year5 years10 years30 years

For purposes of Item B.3., calculate value as the sum of the absolute values of:
(i) the value of each debt security,
(ii) the notional value of each swap, including, but not limited to, total return swaps, interest rate swaps, and credit default swaps, for which the underlying reference asset or assets are debt securities or an interest rate;
(iii) the notional value of each futures contract for which the underlying reference asset or assets are debt securities or an interest rate; and
(iv) the delta-adjusted notional value of any option for which the underlying reference asset is an asset described in clause (i),(ii), or (iii).

Report zero for maturities to which the Fund has no exposure. For exposures that fall between any of the listed maturities in (a) and (b), use linear interpolation to approximate exposure to each maturity listed above. For exposures outside of the range of maturities listed above, include those exposures in the nearest maturity.

Item B.4. Securities lending.

a. For each borrower in any securities lending transaction, provide the following information:

Borrower Information RecordName of borrowerLEI (if any) of borrowerAggregate value of all securities on loan to the borrower
#1BARCLAYS CAPITAL INC.AC28XWWI3WIBK2824319608982.00000000
#2MORGAN STANLEY & CO LLC9R7GPTSO7KV3UQJZQ0781344928.94000000
#3GOLDMAN SACHS & CO.FOR8UP27PHTHYVLBNG301769945.35000000
#4JP MORGAN SECURITIES LLCZBUT11V806EZRVTWT8071298576.00000000
#5CITIGROUP GLOBAL MARKETS INC.MBNUM2BPBDO7JBLYG31019420.00000000
#6National Financial Services LLC549300JRHF1MHHWUAW0425441.00000000

b. Did any securities lending counterparty provide any non-cash collateral? Yes No

Item B.5. Return information.

a. Monthly total returns of the Fund for each of the preceding three months. If the Fund is a Multiple Class Fund, report returns for each class. Such returns shall be calculated in accordance with the methodologies outlined in Item 26(b) (1) of Form N-1A, Instruction 13 to sub-Item 1 of Item 4 of Form N-2, or Item 26(b) (i) of Form N-3, as applicable.

Monthly Total Return Record Monthly total returns of the Fund for each of the preceding three months Class identification number(s) (if any) of the Class(es) for which returns are reported
Month 1 Month 2 Month 3
#1-0.55000000-3.850000002.81000000

b. For each of the preceding three months, monthly net realized gain (loss) and net change in unrealized appreciation (or depreciation) attributable to derivatives for each of the following categories: commodity contracts, credit contracts, equity contracts, foreign exchange contracts, interest rate contracts, and other contracts. Within each such asset category, further report the same information for each of the following types of derivatives instrument: forward, future, option, swaption, swap, warrant, and other. Report in U.S. dollars. Losses and depreciation shall be reported as negative numbers.

Asset category Instrument type Month 1 Month 2 Month 3
Monthly net realized gain(loss) Monthly net change in unrealized appreciation (or depreciation) Monthly net realized gain(loss) Monthly net change in unrealized appreciation (or depreciation) Monthly net realized gain(loss) Monthly net change in unrealized appreciation (or depreciation)
Commodity Contracts
Credit Contracts
Equity Contracts3063737.35000000-1341764.350000001935890.550000001680955.680000002274640.18000000-3545278.98000000
Forward
Future
Option 3063737.35000000-1342688.730000001935890.550000001681143.350000002274640.18000000-3544793.40000000
Swaption
Swap
Warrant 0.00000000924.380000000.00000000-187.670000000.00000000-485.58000000
Other
Foreign Exchange Contracts
Interest Rate Contracts
Other Contracts

c. For each of the preceding three months, monthly net realized gain (loss) and net change in unrealized appreciation (or depreciation) attributable to investment other than derivatives. Report in U.S. dollars. Losses and depreciation shall be reported as negative numbers.

MonthMonthly net realized gain(loss)Monthly net change in unrealized appreciation (or depreciation)
Month 1 1751111.35000000-6869669.17000000
Month 2 -447856.47000000-26188881.93000000
Month 3 7824129.760000008983818.33000000

Item B.6. Flow information.

a. Provide the aggregate dollar amounts for sales and redemptions/repurchases of Fund shares during each of the preceding three months. If shares of the Fund are held in omnibus accounts, for purposes of calculating the Fund's sales, redemptions, and repurchases, use net sales or redemptions/repurchases from such omnibus accounts. The amounts to be reported under this Item should be after any front-end sales load has been deducted and before any deferred or contingent deferred sales load or charge has been deducted. Shares sold shall include shares sold by the Fund to a registered unit investment trust. For mergers and other acquisitions, include in the value of shares sold any transaction in which the Fund acquired the assets of another investment company or of a personal holding company in exchange for its own shares. For liquidations, include in the value of shares redeemed any transaction in which the Fund liquidated all or part of its assets. Exchanges are defined as the redemption or repurchase of shares of one Fund or series and the investment of all or part of the proceeds in shares of another Fund or series in the same family of investment companies.

MonthTotal net asset value of shares sold (including exchanges but excluding reinvestment of dividends and distributions)Total net asset value of shares sold in connection with reinvestments of dividends and distributionsTotal net asset value of shares redeemed or repurchased, including exchanges
Month 1 0.00000000171633.870000000.00000000
Month 2 2056699.69000000169409.930000000.00000000
Month 3 965621.56000000171217.040000000.00000000

Item B.7. Highly Liquid Investment Minimum information.

a. If applicable, provide the Fund's current Highly Liquid Investment Minimum.
b. If applicable, provide the number of days that the Fund's holdings in Highly Liquid Investments fell below the Fund's Highly Liquid Investment Minimum during the reporting period.
c. Did the Fund's Highly Liquid Investment Minimum change during the reporting period? Yes No N/A

Item B.8. Derivatives Transactions.

For portfolio investments of open-end management investment companies, provide the percentage of the Fund's Highly Liquid Investments that it has pledged as margin or collateral in connection with derivatives transactions that are classified among the following categories as specified in rule 22e-4 [17 CFR 270.22e-4]:
(1) Moderately Liquid Investments
(2) Less Liquid Investments
(3) Illiquid Investments
For purposes of Item B.8, when computing the required percentage, the denominator should only include assets (and exclude liabilities) that are categorized by the Fund as Highly Liquid Investments.
Classification

Item B.9. Derivatives Exposure for limited derivatives users.

If the Fund is excepted from the rule 18f-4 [17 CFR 270.18f-4] program requirement and limit on fund leverage risk under rule 18f-4(c)(4) [17 CFR 270.18f-4(c)(4)], provide the following information:
a. Derivatives exposure (as defined in rule 18f-4(a) [17 CFR 270.18f-4(a)]), reported as a percentage of the Fund’s net asset value.
b. Exposure from currency derivatives that hedge currency risks, as provided in rule 18f-4(c)(4)(i)(B) [17 CFR 270.18f-4(c)(4)(i)(B)], reported as a percentage of the Fund's net asset value.
c. Exposure from interest rate derivatives that hedge interest rate risks, as provided in rule 18f-4(c)(4)(i)(B) [17 CFR 270.18f-4(c)(4)(i)(B)], reported as a percentage of the Fund's net asset value.
d. The number of business days, if any, in excess of the five-business-day period described in rule 18f-4(c)(4)(ii) [17 CFR 270.18f-4(c)(4)(ii)], that the Fund’s derivatives exposure exceeded 10 percent of its net assets during the reporting period.

Item B.10. VaR information.

For Funds subject to the limit on fund leverage risk described in rule 18f-4(c)(2) [17 CFR 270.18f-4(c)(2)], provide the following information, as determined in accordance with the requirement under rule 18f-4(c)(2)(ii) to determine the fund’s compliance with the applicable VaR test at least once each business day:
a. Median daily VaR during the reporting period, reported as a percentage of the Fund's net asset value.
b. For Funds that were subject to the Relative VaR Test during the reporting period, provide:
i. As applicable, the name of the Fund’s Designated Index, or a statement that the Fund's Designated Reference Portfolio is the Fund’s Securities Portfolio.
MSCI USA IMI Health Care Call Overwrite Index
ii. As applicable, the index identifier for the Fund’s Designated Index.
N/A
iii. Median VaR Ratio during the reporting period, reported as a percentage of the VaRof the Fund's Designated Reference Portfolio.
c. Backtesting Results. Number of exceptions that the Fund identified as a result of its backtesting of its VaR calculation model (as described in rule 18f-4(c)(1)(iv) [17 CFR 270.18f-4(c)(1)(iv)] during the reporting period.

NPORT-P: Part C: Schedule of Portfolio Investments

For each investment held by the Fund and its consolidated subsidiaries, disclose the information requested in Part C. A Fund may report information for securities in an aggregate amount not exceeding five percent of its total assets as miscellaneous securities in Part D in lieu of reporting those securities in Part C, provided that the securities so listed are not restricted, have been held for not more than one year prior to the end of the reporting period covered by this report, and have not been previously reported by name to the shareholders of the Fund or to any exchange, or set forth in any registration statement, application, or report to shareholders or otherwise made available to the public.
Schedule of Portfolio Investments Record: 1

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ALCON INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95UZY9F8
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-136.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-46580.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00796973903

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
SWITZERLAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Alcon, Inc.
Title of issue.
Alcon, Inc.
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
CH0432492467
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
70.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-29883.29000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 2

Item C.1. Identification of investment.

a. Name of issuer (if any).
Ionis Pharmaceuticals Inc
b. LEI (if any) of issuer. (1)
549300SI4ZGLG0BLUZ92
c. Title of the issue or description of the investment.
Ionis Pharmaceuticals Inc
d. CUSIP (if any).
462222100
At least one of the following other identifiers:
- ISIN
US4622221004

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
18640.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
666193.60000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.113984309518

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 3

Item C.1. Identification of investment.

a. Name of issuer (if any).
TScan Therapeutics Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
TScan Therapeutics Inc
d. CUSIP (if any).
89854M101
At least one of the following other identifiers:
- ISIN
US89854M1018

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
29940.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
62874.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.010757607813

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 4

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ABBOTT LABORATORIES
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960Y4F63
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-15.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-4987.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00085335065

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Abbott Laboratories
Title of issue.
Abbott Laboratories
At least one of the following other identifiers:
- CUSIP.
002824100
- ISIN (if CUSIP is not available).
US0028241000
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
100.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-1120.98000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 5

Item C.1. Identification of investment.

a. Name of issuer (if any).
BARCLAYS BANK PLC
b. LEI (if any) of issuer. (1)
G5GSEF7VJP5I7OUK5573
c. Title of the issue or description of the investment.
APR23 NBIX US C @ 107
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYDUGB79
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-4400.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-1462.30000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00025019642

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1BARCLAYS BANK PLCG5GSEF7VJP5I7OUK5573

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Neurocrine Biosciences, Inc.
Title of issue.
Neurocrine Biosciences, Inc.
At least one of the following other identifiers:
- CUSIP.
64125C109
- ISIN (if CUSIP is not available).
US64125C1099
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
107.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-11
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
13782.82000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 6

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MEDTRONIC PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960YEU80
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-85.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-12622.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00215968293

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Medtronic PLC
Title of issue.
Medtronic PLC
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
IE00BTN1Y115
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
82.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
4017.89000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 7

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
INTUITIVE SURGICAL INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960GBNM3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-48.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-56160.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00960885667

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Intuitive Surgical, Inc.
Title of issue.
Intuitive Surgical, Inc.
At least one of the following other identifiers:
- CUSIP.
46120E602
- ISIN (if CUSIP is not available).
US46120E6023
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
245.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-06
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-37177.09000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 8

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ENCOMPASS HEALTH CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95U068S0
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-156.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-5460.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00093419439

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Encompass Health Corp.
Title of issue.
Encompass Health Corp.
At least one of the following other identifiers:
- CUSIP.
29261A100
- ISIN (if CUSIP is not available).
US29261A1007
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
65.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
18527.71000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 9

Item C.1. Identification of investment.

a. Name of issuer (if any).
10X Genomics Inc
b. LEI (if any) of issuer. (1)
5493003Z6741WNLG7H43
c. Title of the issue or description of the investment.
10X Genomics Inc
d. CUSIP (if any).
88025U109
At least one of the following other identifiers:
- ISIN
US88025U1097

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
9740.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
543394.60000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.092973661525

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 10

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
DANAHER CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960PT965
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-161.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-111895.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01914499675

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Danaher Corp.
Title of issue.
Danaher Corp.
At least one of the following other identifiers:
- CUSIP.
235851102
- ISIN (if CUSIP is not available).
US2358511028
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
250.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-14
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-46683.61000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 11

Item C.1. Identification of investment.

a. Name of issuer (if any).
BNP PARIBAS SA
b. LEI (if any) of issuer. (1)
QHSFEYI7HUOXXZ413E03
c. Title of the issue or description of the investment.
APR23 4568 JP C @ 4411.49
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYEJ3DH5
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-10500.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
Japan Yen
e. Value. (4)
-36864.07000000
f. Exchange rate.
132.77500000
g. Percentage value compared to net assets of the Fund.
-0.00630736405

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1BNP PARIBAS SAQHSFEYI7HUOXXZ413E03

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Daiichi Sankyo Co. Ltd.
Title of issue.
Daiichi Sankyo Co. Ltd.
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
JP3475350009
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
4411.49000000
vi. Exercise Price Currency Code
Japan Yen
vii. Expiration date.
2023-04-13
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-28612.73000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 12

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
GENMAB A/S
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95V33U99
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-64.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-11360.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00194367186

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
DENMARK
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Genmab AS
Title of issue.
Genmab AS
At least one of the following other identifiers:
- CUSIP.
372303206
- ISIN (if CUSIP is not available).
US3723032062
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
40.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-2637.17000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 13

Item C.1. Identification of investment.

a. Name of issuer (if any).
Pliant Therapeutics Inc
b. LEI (if any) of issuer. (1)
5493002Q5LITR7VHZH02
c. Title of the issue or description of the investment.
Pliant Therapeutics Inc
d. CUSIP (if any).
729139105
At least one of the following other identifiers:
- ISIN
US7291391057

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
12594.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
335000.40000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.057317856674

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 14

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
HUMANA INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960664N4
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-32.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-7600.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00130034385

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Humana, Inc.
Title of issue.
Humana, Inc.
At least one of the following other identifiers:
- CUSIP.
444859102
- ISIN (if CUSIP is not available).
US4448591028
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
515.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
21168.43000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 15

Item C.1. Identification of investment.

a. Name of issuer (if any).
NOMURA SECURITIES INTERNATIONAL INC
b. LEI (if any) of issuer. (1)
OXTKY6Q8X53C9ILVV871
c. Title of the issue or description of the investment.
MAY23 HOLX US C @ 80.01
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYF51TC5
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-21.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-6964.13000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00119154784

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1NOMURA SECURITIES INTERNATIONAL INCOXTKY6Q8X53C9ILVV871

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Hologic, Inc.
Title of issue.
Hologic, Inc.
At least one of the following other identifiers:
- CUSIP.
436440101
- ISIN (if CUSIP is not available).
US4364401012
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
80.01000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-1340.99000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 16

Item C.1. Identification of investment.

a. Name of issuer (if any).
Protagonist Therapeutics Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Protagonist Therapeutics Inc
d. CUSIP (if any).
74366E102
At least one of the following other identifiers:
- ISIN
US74366E1029

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
19310.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
444130.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.075989699370

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 17

Item C.1. Identification of investment.

a. Name of issuer (if any).
Rhythm Pharmaceuticals Inc
b. LEI (if any) of issuer. (1)
529900JPNWXQ8DPLA551
c. Title of the issue or description of the investment.
Rhythm Pharmaceuticals Inc
d. CUSIP (if any).
76243J105
At least one of the following other identifiers:
- ISIN
US76243J1051

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
48130.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
858639.20000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.146911342794

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 18

Item C.1. Identification of investment.

a. Name of issuer (if any).
Alnylam Pharmaceuticals Inc
b. LEI (if any) of issuer. (1)
529900S3ZI14OWRJII50
c. Title of the issue or description of the investment.
Alnylam Pharmaceuticals Inc
d. CUSIP (if any).
02043Q107
At least one of the following other identifiers:
- ISIN
US02043Q1076

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
15553.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
3115576.96000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.533068598281

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 19

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ALCON INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9604Z899
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-66.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-3960.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00067754758

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
SWITZERLAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Alcon, Inc.
Title of issue.
Alcon, Inc.
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
CH0432492467
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
75.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
13712.47000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 20

Item C.1. Identification of investment.

a. Name of issuer (if any).
SUSQUEHANNA FINANCIAL GROUP LLLP
b. LEI (if any) of issuer. (1)
549300HN4UKV1E2R3U73
c. Title of the issue or description of the investment.
MAY23 BLCO US C @ 17.5
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYFB3NV8
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-80.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-7236.48000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00123814635

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1SUSQUEHANNA FINANCIAL GROUP LLLP549300HN4UKV1E2R3U73

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Bausch & Lomb Corp.
Title of issue.
Bausch & Lomb Corp.
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
CA0717051076
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
17.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-09
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-3574.84000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 21

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MODERNA INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960YEN39
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-21.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-16222.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00277563528

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Moderna, Inc.
Title of issue.
Moderna, Inc.
At least one of the following other identifiers:
- CUSIP.
60770K107
- ISIN (if CUSIP is not available).
US60770K1079
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
155.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-4699.95000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 22

Item C.1. Identification of investment.

a. Name of issuer (if any).
SUSQUEHANNA FINANCIAL GROUP LLLP
b. LEI (if any) of issuer. (1)
549300E8QX0ZMRDC2M81
c. Title of the issue or description of the investment.
RVMD US FLEX
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYE3V6G0
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-18.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-0.14000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00000002395

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1SUSQUEHANNA FINANCIAL GROUP LLLP549300E8QX0ZMRDC2M81

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
REVOLUTION Medicines, Inc.
Title of issue.
REVOLUTION Medicines, Inc.
At least one of the following other identifiers:
- CUSIP.
76155X100
- ISIN (if CUSIP is not available).
US76155X1000
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
26.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-03
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
3442.66000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 23

Item C.1. Identification of investment.

a. Name of issuer (if any).
BioNTech SE
b. LEI (if any) of issuer. (1)
894500UZJ5LG1F8J1U58
c. Title of the issue or description of the investment.
BioNTech SE
d. CUSIP (if any).
09075V102
At least one of the following other identifiers:
- ISIN
US09075V1026

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
10000.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1245700.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.213136623297

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
GERMANY
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 24

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
STRYKER CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9619WH24
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-233.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-329695.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.05641011400

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Stryker Corp.
Title of issue.
Stryker Corp.
At least one of the following other identifiers:
- CUSIP.
863667101
- ISIN (if CUSIP is not available).
US8636671013
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
280.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-54111.58000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 25

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
STRYKER CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9607NHU6
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-14.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-23450.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00401224517

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Stryker Corp.
Title of issue.
Stryker Corp.
At least one of the following other identifiers:
- CUSIP.
863667101
- ISIN (if CUSIP is not available).
US8636671013
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
270.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-13541.44000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 26

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
WEST PHARMACEUTICAL SERVICES I
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z96087CH4
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-10.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-28350.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00485062476

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
West Pharmaceutical Services, Inc.
Title of issue.
West Pharmaceutical Services, Inc.
At least one of the following other identifiers:
- CUSIP.
955306105
- ISIN (if CUSIP is not available).
US9553061055
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
320.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-13415.24000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 27

Item C.1. Identification of investment.

a. Name of issuer (if any).
Vertex Pharmaceuticals Inc
b. LEI (if any) of issuer. (1)
54930015RAQRRZ5ZGJ91
c. Title of the issue or description of the investment.
Vertex Pharmaceuticals Inc
d. CUSIP (if any).
92532F100
At least one of the following other identifiers:
- ISIN
US92532F1003

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
47119.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
14845783.33000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
2.540081985363

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
i. If Yes, provide the value of the securities on loan.
976717.00000000
Schedule of Portfolio Investments Record: 28

Item C.1. Identification of investment.

a. Name of issuer (if any).
JANE STREET EXECUTION SERVICES, LLC
b. LEI (if any) of issuer. (1)
549300HN4UKV1E2R3U73
c. Title of the issue or description of the investment.
APR23 ZTS US C @ 167.00
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYFB6EG4
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-166.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-82038.53000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01403661817

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1JANE STREET EXECUTION SERVICES, LLC549300HN4UKV1E2R3U73

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Zoetis, Inc.
Title of issue.
Zoetis, Inc.
At least one of the following other identifiers:
- CUSIP.
98978V103
- ISIN (if CUSIP is not available).
US98978V1035
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
167.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-27
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
10550.70000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 29

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ALIGN TECHNOLOGY INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960Y40J1
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-15.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-32475.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00555640350

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Align Technology, Inc.
Title of issue.
Align Technology, Inc.
At least one of the following other identifiers:
- CUSIP.
016255101
- ISIN (if CUSIP is not available).
US0162551016
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
330.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-1919.11000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 30

Item C.1. Identification of investment.

a. Name of issuer (if any).
Johnson & Johnson
b. LEI (if any) of issuer. (1)
549300G0CFPGEF6X2043
c. Title of the issue or description of the investment.
Johnson & Johnson
d. CUSIP (if any).
478160104
At least one of the following other identifiers:
- ISIN
US4781601046

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
101374.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
15712970.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
2.688455782114

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 31

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MERCK + CO INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960GF4F0
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-234.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-4446.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00076070115

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Merck & Co., Inc.
Title of issue.
Merck & Co., Inc.
At least one of the following other identifiers:
- CUSIP.
58933Y105
- ISIN (if CUSIP is not available).
US58933Y1055
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
109.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-06
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
36901.56000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 32

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
GILEAD SCIENCES INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960YTZY5
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-141.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-44274.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00757518733

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Gilead Sciences, Inc.
Title of issue.
Gilead Sciences, Inc.
At least one of the following other identifiers:
- CUSIP.
375558103
- ISIN (if CUSIP is not available).
US3755581036
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
81.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-21145.18000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 33

Item C.1. Identification of investment.

a. Name of issuer (if any).
UnitedHealth Group Inc
b. LEI (if any) of issuer. (1)
549300GHBMY8T5GXDE41
c. Title of the issue or description of the investment.
UnitedHealth Group Inc
d. CUSIP (if any).
91324P102
At least one of the following other identifiers:
- ISIN
US91324P1021

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
92029.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
43491985.11000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
7.441386246178

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 34

Item C.1. Identification of investment.

a. Name of issuer (if any).
Exact Sciences Corp
b. LEI (if any) of issuer. (1)
549300VM3X1FYD4N9Z14
c. Title of the issue or description of the investment.
Exact Sciences Corp
d. CUSIP (if any).
30063P105
At least one of the following other identifiers:
- ISIN
US30063P1057

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
16381.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1110795.61000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.190054768796

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 35

Item C.1. Identification of investment.

a. Name of issuer (if any).
Omnicell Inc
b. LEI (if any) of issuer. (1)
5493008RH0GTKHHPZI77
c. Title of the issue or description of the investment.
Omnicell Inc
d. CUSIP (if any).
68213N109
At least one of the following other identifiers:
- ISIN
US68213N1090

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
6425.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
376954.75000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.064496156820

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 36

Item C.1. Identification of investment.

a. Name of issuer (if any).
JANE STREET EXECUTION SERVICES, LLC
b. LEI (if any) of issuer. (1)
549300HN4UKV1E2R3U73
c. Title of the issue or description of the investment.
MAY23 ARVN US C @ 31.65
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYF6XBW9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-15.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-2562.36000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00043841435

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1JANE STREET EXECUTION SERVICES, LLC549300HN4UKV1E2R3U73

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
International Business Machines Corp.
Title of issue.
International Business Machines Corp.
At least one of the following other identifiers:
- CUSIP.
459200101
- ISIN (if CUSIP is not available).
US4592001014
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
31.65000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
1199.16000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 37

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
LEGEND BIOTECH CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9606FJ57
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-27.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-2160.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00036957141

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
CAYMAN ISLANDS
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Legend Biotech Corp.
Title of issue.
Legend Biotech Corp.
At least one of the following other identifiers:
- CUSIP.
52490G102
- ISIN (if CUSIP is not available).
US52490G1022
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
50.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
4119.98000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 38

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
VERTEX PHARMACEUTICALS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9602HS16
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-69.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-79350.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01357661640

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Vertex Pharmaceuticals, Inc.
Title of issue.
Vertex Pharmaceuticals, Inc.
At least one of the following other identifiers:
- CUSIP.
92532F100
- ISIN (if CUSIP is not available).
US92532F1003
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
305.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-03-31
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-52088.12000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 39

Item C.1. Identification of investment.

a. Name of issuer (if any).
Repligen Corp
b. LEI (if any) of issuer. (1)
54930006QJ0T5AUO1E71
c. Title of the issue or description of the investment.
Repligen Corp
d. CUSIP (if any).
759916109
At least one of the following other identifiers:
- ISIN
US7599161095

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
8190.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1378868.40000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.235921453598

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 40

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
NOVOCURE LTD
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95QNAF57
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-54.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-2970.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00050816068

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
JERSEY
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Novocure Ltd.
Title of issue.
Novocure Ltd.
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
JE00BYSS4X48
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
75.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
11998.30000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 41

Item C.1. Identification of investment.

a. Name of issuer (if any).
LARONDE INC SERIES B
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
LARONDE INC SERIES B
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRWPUMHD2
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
21100.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
531720.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.090976162270

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 42

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
GILEAD SCIENCES INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960RRGR3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-295.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-72422.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01239133587

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Gilead Sciences, Inc.
Title of issue.
Gilead Sciences, Inc.
At least one of the following other identifiers:
- CUSIP.
375558103
- ISIN (if CUSIP is not available).
US3755581036
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
81.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-14
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-42737.56000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 43

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
PTC THERAPEUTICS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z96071Y84
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-24.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-8580.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00146801977

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
PTC Therapeutics, Inc.
Title of issue.
PTC Therapeutics, Inc.
At least one of the following other identifiers:
- CUSIP.
69366J200
- ISIN (if CUSIP is not available).
US69366J2006
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
48.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-400.81000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 44

Item C.1. Identification of investment.

a. Name of issuer (if any).
QIAGEN NV
b. LEI (if any) of issuer. (1)
54930036WK3GMCN17Z57
c. Title of the issue or description of the investment.
QIAGEN NV
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- ISIN
NL0012169213

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
31011.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1424335.23000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.243700731609

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
NETHERLANDS
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 45

Item C.1. Identification of investment.

a. Name of issuer (if any).
Tenaya Therapeutics Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Tenaya Therapeutics Inc
d. CUSIP (if any).
87990A106
At least one of the following other identifiers:
- ISIN
US87990A1060

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
25502.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
72680.70000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.012435513347

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 46

Item C.1. Identification of investment.

a. Name of issuer (if any).
Genmab A/S
b. LEI (if any) of issuer. (1)
529900MTJPDPE4MHJ122
c. Title of the issue or description of the investment.
Genmab A/S
d. CUSIP (if any).
372303206
At least one of the following other identifiers:
- ISIN
US3723032062

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
16911.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
638559.36000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.109256149767

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
DENMARK
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
i. If Yes, provide the value of the securities on loan.
255408.64000000
Schedule of Portfolio Investments Record: 47

Item C.1. Identification of investment.

a. Name of issuer (if any).
AbbVie Inc
b. LEI (if any) of issuer. (1)
FR5LCKFTG8054YNNRU85
c. Title of the issue or description of the investment.
AbbVie Inc
d. CUSIP (if any).
00287Y109
At least one of the following other identifiers:
- ISIN
US00287Y1091

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
111783.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
17814856.71000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
3.048084132378

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 48

Item C.1. Identification of investment.

a. Name of issuer (if any).
Prometheus Biosciences Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Prometheus Biosciences Inc
d. CUSIP (if any).
74349U108
At least one of the following other identifiers:
- ISIN
US74349U1088

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
6920.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
742654.40000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.127066589944

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 49

Item C.1. Identification of investment.

a. Name of issuer (if any).
NOMURA SECURITIES INTERNATIONAL INC
b. LEI (if any) of issuer. (1)
OXTKY6Q8X53C9ILVV871
c. Title of the issue or description of the investment.
AVTR US FLEX
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYDVXMS3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-75.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-0.01000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00000000171

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1NOMURA SECURITIES INTERNATIONAL INCOXTKY6Q8X53C9ILVV871

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Avantor, Inc.
Title of issue.
Avantor, Inc.
At least one of the following other identifiers:
- CUSIP.
05352A100
- ISIN (if CUSIP is not available).
US05352A1007
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
25.29000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-03
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
5007.69000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 50

Item C.1. Identification of investment.

a. Name of issuer (if any).
Frequency Therapeutics Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Frequency Therapeutics Inc
d. CUSIP (if any).
35803L108
At least one of the following other identifiers:
- ISIN
US35803L1089

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
28060.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
14114.18000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.002414906210

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 51

Item C.1. Identification of investment.

a. Name of issuer (if any).
Agiliti Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Agiliti Inc
d. CUSIP (if any).
00848J104
At least one of the following other identifiers:
- ISIN
US00848J1043

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
40496.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
647126.08000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.110721897358

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 52

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
RESMED INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9619LBS7
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-21.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-18795.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00321578456

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
ResMed, Inc.
Title of issue.
ResMed, Inc.
At least one of the following other identifiers:
- CUSIP.
761152107
- ISIN (if CUSIP is not available).
US7611521078
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
220.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-7102.91000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 53

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
IQVIA HOLDINGS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960683X9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-69.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-2242.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00038368698

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
IQVIA Holdings, Inc.
Title of issue.
IQVIA Holdings, Inc.
At least one of the following other identifiers:
- CUSIP.
46266C105
- ISIN (if CUSIP is not available).
US46266C1053
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
220.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
69087.16000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 54

Item C.1. Identification of investment.

a. Name of issuer (if any).
Thermo Fisher Scientific Inc
b. LEI (if any) of issuer. (1)
HCHV7422L5HDJZCRFL38
c. Title of the issue or description of the investment.
Thermo Fisher Scientific Inc
d. CUSIP (if any).
883556102
At least one of the following other identifiers:
- ISIN
US8835561023

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
50138.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
28898039.06000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
4.944393084351

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 55

Item C.1. Identification of investment.

a. Name of issuer (if any).
PMV Pharmaceuticals Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
PMV Pharmaceuticals Inc
d. CUSIP (if any).
69353Y103
At least one of the following other identifiers:
- ISIN
US69353Y1038

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
17490.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
83427.30000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.014274233774

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 56

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
METTLER-TOLEDO INTERNATIONAL I
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95Z4UTR1
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-4.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-3800.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00065017192

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Mettler-Toledo International, Inc.
Title of issue.
Mettler-Toledo International, Inc.
At least one of the following other identifiers:
- CUSIP.
592688105
- ISIN (if CUSIP is not available).
US5926881054
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
1610.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
7511.38000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 57

Item C.1. Identification of investment.

a. Name of issuer (if any).
MORGAN STANLEY & CO. INTERNATIONAL
b. LEI (if any) of issuer. (1)
4PQUHN3JPFGFNF3BB653
c. Title of the issue or description of the investment.
APR23 SAN FP C @ 90.47
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYEL1V78
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-4700.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
Euro Member Countries
e. Value. (4)
-49991.57000000
f. Exchange rate.
0.92208400
g. Percentage value compared to net assets of the Fund.
-0.00855345141

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1MORGAN STANLEY & CO. INTERNATIONAL4PQUHN3JPFGFNF3BB653

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Sanofi
Title of issue.
Sanofi
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
FR0000120578
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
90.47000000
vi. Exercise Price Currency Code
Euro Member Countries
vii. Expiration date.
2023-04-05
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-41754.70000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 58

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
COOPER COS INC/THE
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9605AG11
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-18.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-46710.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00799198175

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Cooper Cos., Inc.
Title of issue.
Cooper Cos., Inc.
At least one of the following other identifiers:
- CUSIP.
216648402
- ISIN (if CUSIP is not available).
US2166484020
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
350.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-24031.47000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 59

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
HCA HEALTHCARE INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95ZR28W0
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-30.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-25950.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00443998986

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
HCA Healthcare, Inc.
Title of issue.
HCA Healthcare, Inc.
At least one of the following other identifiers:
- CUSIP.
40412C101
- ISIN (if CUSIP is not available).
US40412C1018
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
265.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
6896.87000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 60

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ABBVIE INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960PLXR9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-105.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-102112.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01747123179

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
AbbVie, Inc.
Title of issue.
AbbVie, Inc.
At least one of the following other identifiers:
- CUSIP.
00287Y109
- ISIN (if CUSIP is not available).
US00287Y1091
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
150.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-14
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-68995.35000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 61

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
BIONTECH SE
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960G5D70
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-38.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-380.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00006501719

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
GERMANY
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
BioNTech SE
Title of issue.
BioNTech SE
At least one of the following other identifiers:
- CUSIP.
09075V102
- ISIN (if CUSIP is not available).
US09075V1026
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
140.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-06
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
12122.69000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 62

Item C.1. Identification of investment.

a. Name of issuer (if any).
Agilent Technologies Inc
b. LEI (if any) of issuer. (1)
QUIX8Y7A2WP0XRMW7G29
c. Title of the issue or description of the investment.
Agilent Technologies Inc
d. CUSIP (if any).
00846U101
At least one of the following other identifiers:
- ISIN
US00846U1016

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
25861.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
3577610.74000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.612121596369

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 63

Item C.1. Identification of investment.

a. Name of issuer (if any).
Cellarity, Inc. series B
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Cellarity, Inc. series B
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRWE8YSX0
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
44167.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
174459.65000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.029849675445

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 64

Item C.1. Identification of investment.

a. Name of issuer (if any).
BioMarin Pharmaceutical Inc
b. LEI (if any) of issuer. (1)
NSLL8ITTRR0J5HEMR848
c. Title of the issue or description of the investment.
BioMarin Pharmaceutical Inc
d. CUSIP (if any).
09061G101
At least one of the following other identifiers:
- ISIN
US09061G1013

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
34910.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
3394648.40000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.580817128730

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 65

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ABBVIE INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960Y3DM2
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-118.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-73160.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01251752055

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
AbbVie, Inc.
Title of issue.
AbbVie, Inc.
At least one of the following other identifiers:
- CUSIP.
00287Y109
- ISIN (if CUSIP is not available).
US00287Y1091
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
155.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-10482.38000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 66

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
BIOGEN INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960Y4UV1
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-80.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-101600.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01738354413

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Biogen, Inc.
Title of issue.
Biogen, Inc.
At least one of the following other identifiers:
- CUSIP.
09062X103
- ISIN (if CUSIP is not available).
US09062X1037
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
275.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-52818.72000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 67

Item C.1. Identification of investment.

a. Name of issuer (if any).
Sigilon Therapeutics Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Sigilon Therapeutics Inc
d. CUSIP (if any).
82657L107
At least one of the following other identifiers:
- ISIN
US82657L1070

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
19555.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
18188.11000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.003111946977

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 68

Item C.1. Identification of investment.

a. Name of issuer (if any).
Nucleix Limited, SERIES AA
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Nucleix Limited, SERIES AA
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRWJZLGM4
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
367395.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1036053.90000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.177266621016

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-preferred
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 69

Item C.1. Identification of investment.

a. Name of issuer (if any).
Sage Therapeutics Inc
b. LEI (if any) of issuer. (1)
5493000JX4BJS9W6CN35
c. Title of the issue or description of the investment.
Sage Therapeutics Inc
d. CUSIP (if any).
78667J108
At least one of the following other identifiers:
- ISIN
US78667J1088

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
21680.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
909692.80000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.155646505282

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 70

Item C.1. Identification of investment.

a. Name of issuer (if any).
Swift Health Systems Inc., SERIES D
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Swift Health Systems Inc., SERIES D
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRWRG7ZC9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
92580.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
133315.20000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.022809947469

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 71

Item C.1. Identification of investment.

a. Name of issuer (if any).
Novo Nordisk A/S
b. LEI (if any) of issuer. (1)
549300DAQ1CVT6CXN342
c. Title of the issue or description of the investment.
Novo Nordisk A/S
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- ISIN
DK0060534915

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
26375.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
Denmark Krone
e. Value. (4)
4188910.68000000
f. Exchange rate.
6.86935000
g. Percentage value compared to net assets of the Fund.
0.716713717292

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
DENMARK
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 72

Item C.1. Identification of investment.

a. Name of issuer (if any).
SUSQUEHANNA FINANCIAL GROUP LLLP
b. LEI (if any) of issuer. (1)
549300HN4UKV1E2R3U73
c. Title of the issue or description of the investment.
MAY23 CTLT US C @ 70.5
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYF7HT38
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-38.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-20284.02000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00347055272

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1SUSQUEHANNA FINANCIAL GROUP LLLP549300HN4UKV1E2R3U73

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Catalent, Inc.
Title of issue.
Catalent, Inc.
At least one of the following other identifiers:
- CUSIP.
148806102
- ISIN (if CUSIP is not available).
US1488061029
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
70.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
5813.07000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 73

Item C.1. Identification of investment.

a. Name of issuer (if any).
iRhythm Technologies Inc
b. LEI (if any) of issuer. (1)
549300FJI72RJGDQS384
c. Title of the issue or description of the investment.
iRhythm Technologies Inc
d. CUSIP (if any).
450056106
At least one of the following other identifiers:
- ISIN
US4500561067

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
2280.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
282788.40000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.048384494407

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 74

Item C.1. Identification of investment.

a. Name of issuer (if any).
JEFFERIES LLC
b. LEI (if any) of issuer. (1)
58PU97L1C0WSRCWADL48
c. Title of the issue or description of the investment.
A US FLEX
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYDZ81D0
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-94.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-616.55000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00010549039

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1JEFFERIES LLC58PU97L1C0WSRCWADL48

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Agilent Technologies, Inc.
Title of issue.
Agilent Technologies, Inc.
At least one of the following other identifiers:
- CUSIP.
00846U101
- ISIN (if CUSIP is not available).
US00846U1016
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
159.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
37619.03000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 75

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
GE HEALTHCARE TECHNOLOGIES INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960RQK58
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-260.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-76700.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01312320703

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
GE HealthCare Technologies, Inc.
Title of issue.
GE HealthCare Technologies, Inc.
At least one of the following other identifiers:
- CUSIP.
36266G107
- ISIN (if CUSIP is not available).
US36266G1076
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
80.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-14
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-48679.78000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 76

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
WATERS CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9608AAX4
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-40.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-6600.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00112924597

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Waters Corp.
Title of issue.
Waters Corp.
At least one of the following other identifiers:
- CUSIP.
941848103
- ISIN (if CUSIP is not available).
US9418481035
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
340.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
30785.58000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 77

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
AMERISOURCEBERGEN CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960Y4BM2
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-81.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-24907.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00426162032

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
AmerisourceBergen Corp.
Title of issue.
AmerisourceBergen Corp.
At least one of the following other identifiers:
- CUSIP.
03073E105
- ISIN (if CUSIP is not available).
US03073E1055
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
160.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-6458.20000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 78

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
GLAUKOS CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z961AUPZ4
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-9.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-2115.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00036187200

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Glaukos Corp.
Title of issue.
Glaukos Corp.
At least one of the following other identifiers:
- CUSIP.
377322102
- ISIN (if CUSIP is not available).
US3773221029
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
52.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-63.28000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 79

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ARCUTIS BIOTHERAPEUTICS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9608LXM9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-162.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-5670.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00097012495

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Arcutis Biotherapeutics, Inc.
Title of issue.
Arcutis Biotherapeutics, Inc.
At least one of the following other identifiers:
- CUSIP.
03969K108
- ISIN (if CUSIP is not available).
US03969K1088
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
12.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-171.23000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 80

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
PFIZER INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z961L3618
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-427.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-29676.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00507758609

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Pfizer, Inc.
Title of issue.
Pfizer, Inc.
At least one of the following other identifiers:
- CUSIP.
717081103
- ISIN (if CUSIP is not available).
US7170811035
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
42.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-05
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-3491.52000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 81

Item C.1. Identification of investment.

a. Name of issuer (if any).
JANE STREET EXECUTION SERVICES, LLC
b. LEI (if any) of issuer. (1)
549300HXJLXCPDWAH070
c. Title of the issue or description of the investment.
PODD US FLEX
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYDVVH20
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-6.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-8516.41000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00145713965

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1JANE STREET EXECUTION SERVICES, LLC549300HXJLXCPDWAH070

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Insulet Corp.
Title of issue.
Insulet Corp.
At least one of the following other identifiers:
- CUSIP.
45784P101
- ISIN (if CUSIP is not available).
US45784P1012
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
312.52000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
968.00000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 82

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
IONIS PHARMACEUTICALS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95U0P049
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-41.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-205.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00003507506

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Ionis Pharmaceuticals, Inc.
Title of issue.
Ionis Pharmaceuticals, Inc.
At least one of the following other identifiers:
- CUSIP.
462222100
- ISIN (if CUSIP is not available).
US4622221004
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
40.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
7698.42000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 83

Item C.1. Identification of investment.

a. Name of issuer (if any).
Alcon Inc
b. LEI (if any) of issuer. (1)
549300LDT5AP8S0NBM78
c. Title of the issue or description of the investment.
Alcon Inc
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- ISIN
CH0432492467

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
88739.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
6259649.06000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
1.071012654473

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
SWITZERLAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 84

Item C.1. Identification of investment.

a. Name of issuer (if any).
Horizon Therapeutics Plc
b. LEI (if any) of issuer. (1)
529900P0GSQ79OOZEV53
c. Title of the issue or description of the investment.
Horizon Therapeutics Plc
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- ISIN
IE00BQPVQZ61

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
7410.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
808727.40000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.138371539860

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 85

Item C.1. Identification of investment.

a. Name of issuer (if any).
Seagen Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Seagen Inc
d. CUSIP (if any).
81181C104
At least one of the following other identifiers:
- ISIN
US81181C1045

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
20872.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
4225953.84000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.723051723264

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 86

Item C.1. Identification of investment.

a. Name of issuer (if any).
Novocure Ltd
b. LEI (if any) of issuer. (1)
213800YPP55UMHWA4826
c. Title of the issue or description of the investment.
Novocure Ltd
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- ISIN
JE00BYSS4X48

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
27700.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1665878.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.285028186357

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
JERSEY
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
i. If Yes, provide the value of the securities on loan.
666351.20000000
Schedule of Portfolio Investments Record: 87

Item C.1. Identification of investment.

a. Name of issuer (if any).
Medtronic PLC
b. LEI (if any) of issuer. (1)
549300GX3ZBSQWUXY261
c. Title of the issue or description of the investment.
Medtronic PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- ISIN
IE00BTN1Y115

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
137740.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
11104598.80000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
1.899973261065

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 88

Item C.1. Identification of investment.

a. Name of issuer (if any).
Centene Corp
b. LEI (if any) of issuer. (1)
549300Z7JJ4TQSQGT333
c. Title of the issue or description of the investment.
Centene Corp
d. CUSIP (if any).
15135B101
At least one of the following other identifiers:
- ISIN
US15135B1017

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
29311.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1852748.31000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.317001299361

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 89

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
AMGEN INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960G2YL3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-126.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-42210.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00722204131

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Amgen, Inc.
Title of issue.
Amgen, Inc.
At least one of the following other identifiers:
- CUSIP.
031162100
- ISIN (if CUSIP is not available).
US0311621009
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
240.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-06
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
16063.17000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 90

Item C.1. Identification of investment.

a. Name of issuer (if any).
Monte Rosa Therapeutics Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Monte Rosa Therapeutics Inc
d. CUSIP (if any).
61225M102
At least one of the following other identifiers:
- ISIN
US61225M1027

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
28575.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
222599.25000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.038086258724

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 91

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
QUEST DIAGNOSTICS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9605HT12
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-156.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-50700.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00867466227

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Quest Diagnostics, Inc.
Title of issue.
Quest Diagnostics, Inc.
At least one of the following other identifiers:
- CUSIP.
74834L100
- ISIN (if CUSIP is not available).
US74834L1008
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
140.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-32327.88000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 92

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
WEST PHARMACEUTICAL SERVICES I
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z961A3N03
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-10.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-13050.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00223282727

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
West Pharmaceutical Services, Inc.
Title of issue.
West Pharmaceutical Services, Inc.
At least one of the following other identifiers:
- CUSIP.
955306105
- ISIN (if CUSIP is not available).
US9553061055
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
360.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-4572.36000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 93

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ICON PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95U0R8A3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-31.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-7750.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00132600853

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
ICON PLC
Title of issue.
ICON PLC
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
IE0005711209
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
240.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
20838.99000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 94

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
JOHNSON + JOHNSON
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z96003B33
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-161.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-35098.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00600519322

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Johnson & Johnson
Title of issue.
Johnson & Johnson
At least one of the following other identifiers:
- CUSIP.
478160104
- ISIN (if CUSIP is not available).
US4781601046
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
160.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-1325.16000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 95

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MCKESSON CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960YEXS3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-22.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-27170.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00464872927

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
McKesson Corp.
Title of issue.
McKesson Corp.
At least one of the following other identifiers:
- CUSIP.
58155Q103
- ISIN (if CUSIP is not available).
US58155Q1031
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
350.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-14181.65000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 96

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ALNYLAM PHARMACEUTICALS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z96051LJ6
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-43.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-38270.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00654791568

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Alnylam Pharmaceuticals, Inc.
Title of issue.
Alnylam Pharmaceuticals, Inc.
At least one of the following other identifiers:
- CUSIP.
02043Q107
- ISIN (if CUSIP is not available).
US02043Q1076
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
200.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-18491.17000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 97

Item C.1. Identification of investment.

a. Name of issuer (if any).
JANE STREET EXECUTION SERVICES, LLC
b. LEI (if any) of issuer. (1)
549300HXJLXCPDWAH070
c. Title of the issue or description of the investment.
CERE US FLEX
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYDZZ6E3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-32.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-101.79000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00001741605

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1JANE STREET EXECUTION SERVICES, LLC549300HXJLXCPDWAH070

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Cerevel Therapeutics Holdings, Inc.
Title of issue.
Cerevel Therapeutics Holdings, Inc.
At least one of the following other identifiers:
- CUSIP.
15678U128
- ISIN (if CUSIP is not available).
US15678U1280
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
37.38000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-17
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
6482.72000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 98

Item C.1. Identification of investment.

a. Name of issuer (if any).
Genmab A/S
b. LEI (if any) of issuer. (1)
529900MTJPDPE4MHJ122
c. Title of the issue or description of the investment.
Genmab A/S
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- ISIN
DK0010272202

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
2498.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
Denmark Krone
e. Value. (4)
944257.16000000
f. Exchange rate.
6.86935000
g. Percentage value compared to net assets of the Fund.
0.161560393840

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
DENMARK
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 99

Item C.1. Identification of investment.

a. Name of issuer (if any).
Roche Holding AG
b. LEI (if any) of issuer. (1)
549300U41AUUVOAAOB37
c. Title of the issue or description of the investment.
Roche Holding AG
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- ISIN
CH0012032048

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
6561.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
Switzerland Franc
e. Value. (4)
1874756.28000000
f. Exchange rate.
0.91495000
g. Percentage value compared to net assets of the Fund.
0.320766816268

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
SWITZERLAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 100

Item C.1. Identification of investment.

a. Name of issuer (if any).
Zoetis Inc
b. LEI (if any) of issuer. (1)
549300HD9Q1LOC9KLJ48
c. Title of the issue or description of the investment.
Zoetis Inc
d. CUSIP (if any).
98978V103
At least one of the following other identifiers:
- ISIN
US98978V1035

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
80144.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
13339167.36000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
2.282303193959

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 101

Item C.1. Identification of investment.

a. Name of issuer (if any).
Boston Scientific Corp
b. LEI (if any) of issuer. (1)
Y6ZDD9FP4P8JSSJMW954
c. Title of the issue or description of the investment.
Boston Scientific Corp
d. CUSIP (if any).
101137107
At least one of the following other identifiers:
- ISIN
US1011371077

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
432925.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
21659237.75000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
3.705849560279

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 102

Item C.1. Identification of investment.

a. Name of issuer (if any).
Zimmer Biomet Holdings Inc
b. LEI (if any) of issuer. (1)
2P2YLDVPES3BXQ1FRB91
c. Title of the issue or description of the investment.
Zimmer Biomet Holdings Inc
d. CUSIP (if any).
98956P102
At least one of the following other identifiers:
- ISIN
US98956P1021

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
14617.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1888516.40000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.323121143564

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 103

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MERCK + CO INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960YEQB8
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-244.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-43188.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00738937503

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Merck & Co., Inc.
Title of issue.
Merck & Co., Inc.
At least one of the following other identifiers:
- CUSIP.
58933Y105
- ISIN (if CUSIP is not available).
US58933Y1055
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
109.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
18375.61000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 104

Item C.1. Identification of investment.

a. Name of issuer (if any).
ResMed Inc
b. LEI (if any) of issuer. (1)
529900T3QE5253CCXF22
c. Title of the issue or description of the investment.
ResMed Inc
d. CUSIP (if any).
761152107
At least one of the following other identifiers:
- ISIN
US7611521078

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
14439.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
3161996.61000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.541010901769

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 105

Item C.1. Identification of investment.

a. Name of issuer (if any).
Elevance Health Inc
b. LEI (if any) of issuer. (1)
8MYN82XMYQH89CTMTH67
c. Title of the issue or description of the investment.
Elevance Health Inc
d. CUSIP (if any).
036752103
At least one of the following other identifiers:
- ISIN
US0367521038

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
12737.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
5856599.97000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
1.002051811521

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 106

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ELI LILLY + CO
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960Q56B8
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-119.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-132090.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.02260031835

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Eli Lilly & Co.
Title of issue.
Eli Lilly & Co.
At least one of the following other identifiers:
- CUSIP.
532457108
- ISIN (if CUSIP is not available).
US5324571083
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
335.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-14
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-43224.98000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 107

Item C.1. Identification of investment.

a. Name of issuer (if any).
Apellis Pharmaceuticals Inc
b. LEI (if any) of issuer. (1)
254900HS0ZFRXXSB9D42
c. Title of the issue or description of the investment.
Apellis Pharmaceuticals Inc
d. CUSIP (if any).
03753U106
At least one of the following other identifiers:
- ISIN
US03753U1060

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
13695.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
903322.20000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.154556509157

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 108

Item C.1. Identification of investment.

a. Name of issuer (if any).
Biogen Inc
b. LEI (if any) of issuer. (1)
W8J5WZB5IY3K0NDQT671
c. Title of the issue or description of the investment.
Biogen Inc
d. CUSIP (if any).
09062X103
At least one of the following other identifiers:
- ISIN
US09062X1037

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
21312.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
5925375.36000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
1.013819134625

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 109

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MASIMO CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9606Q9B1
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-17.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-36465.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00623908402

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Masimo Corp.
Title of issue.
Masimo Corp.
At least one of the following other identifiers:
- CUSIP.
574795100
- ISIN (if CUSIP is not available).
US5747951003
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
165.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-19919.41000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 110

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
HORIZON THERAPEUTICS PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z96065463
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-28.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-1750.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00029942128

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Horizon Therapeutics PLC
Title of issue.
Horizon Therapeutics PLC
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
IE00BQPVQZ61
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
110.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
1820.30000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 111

Item C.1. Identification of investment.

a. Name of issuer (if any).
SUSQUEHANNA FINANCIAL GROUP LLLP
b. LEI (if any) of issuer. (1)
549300HN4UKV1E2R3U73
c. Title of the issue or description of the investment.
MAY23 WST US C @ 329
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYF8W0D3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-38.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-111865.96000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01914002807

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1SUSQUEHANNA FINANCIAL GROUP LLLP549300HN4UKV1E2R3U73

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
West Pharmaceutical Services, Inc.
Title of issue.
West Pharmaceutical Services, Inc.
At least one of the following other identifiers:
- CUSIP.
955306105
- ISIN (if CUSIP is not available).
US9553061055
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
329.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-47351.18000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 112

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
DESIGN THERAPEUTICS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95UJ7CJ3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-26.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-520.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00008897089

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Design Therapeutics, Inc.
Title of issue.
Design Therapeutics, Inc.
At least one of the following other identifiers:
- CUSIP.
25056L103
- ISIN (if CUSIP is not available).
US25056L1035
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
10.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
228.02000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 113

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
REGENERON PHARMACEUTICALS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z96026WA5
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-23.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-118450.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.02026654333

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Regeneron Pharmaceuticals, Inc.
Title of issue.
Regeneron Pharmaceuticals, Inc.
At least one of the following other identifiers:
- CUSIP.
75886F107
- ISIN (if CUSIP is not available).
US75886F1075
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
770.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-03-31
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-75423.51000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 114

Item C.1. Identification of investment.

a. Name of issuer (if any).
CONTRA ABIOMED INC
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
CONTRA ABIOMED INC
d. CUSIP (if any).
003CVR016
At least one of the following other identifiers:
- ISIN
US003CVR0169

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
14359.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
40061.61000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.006854456353

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 115

Item C.1. Identification of investment.

a. Name of issuer (if any).
MORGAN STANLEY & CO. INTERNATIONAL
b. LEI (if any) of issuer. (1)
4PQUHN3JPFGFNF3BB653
c. Title of the issue or description of the investment.
APR23 GMAB DC C @ 2707.9100
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYEL1VJ2
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-900.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
Denmark Krone
e. Value. (4)
-263.16000000
f. Exchange rate.
6.86935000
g. Percentage value compared to net assets of the Fund.
-0.00004502611

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1MORGAN STANLEY & CO. INTERNATIONAL4PQUHN3JPFGFNF3BB653

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Genmab AS
Title of issue.
Genmab AS
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
DK0010272202
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
2707.91000000
vi. Exercise Price Currency Code
Denmark Krone
vii. Expiration date.
2023-04-05
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
6832.32000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 116

Item C.1. Identification of investment.

a. Name of issuer (if any).
BARCLAYS BANK PLC
b. LEI (if any) of issuer. (1)
G5GSEF7VJP5I7OUK5573
c. Title of the issue or description of the investment.
MAY23 RYTM US C @ 28
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYEEFQ89
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-6700.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-1495.84000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00025593504

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1BARCLAYS BANK PLCG5GSEF7VJP5I7OUK5573

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Rhythm Pharmaceuticals, Inc.
Title of issue.
Rhythm Pharmaceuticals, Inc.
At least one of the following other identifiers:
- CUSIP.
76243J105
- ISIN (if CUSIP is not available).
US76243J1051
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
28.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-04
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
9876.07000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 117

Item C.1. Identification of investment.

a. Name of issuer (if any).
Daiichi Sankyo Co Ltd
b. LEI (if any) of issuer. (1)
353800XGIU2IHQGC9504
c. Title of the issue or description of the investment.
Daiichi Sankyo Co Ltd
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- ISIN
JP3475350009

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
106000.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
Japan Yen
e. Value. (4)
3866629.37000000
f. Exchange rate.
132.77500000
g. Percentage value compared to net assets of the Fund.
0.661572069893

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
JAPAN
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 118

Item C.1. Identification of investment.

a. Name of issuer (if any).
Nuvation Bio Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Nuvation Bio Inc
d. CUSIP (if any).
67080N119
At least one of the following other identifiers:
- ISIN
US67080N1191

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
4050.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
486.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.000083153567

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Warrant
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1N/AN/A

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Nuvation Bio Inc
Title of issue.
Nuvation Bio Inc
At least one of the following other identifiers:
- CUSIP.
67080N101
- ISIN (if CUSIP is not available).
US67080N1019
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
11.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2027-07-07
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-7570.78000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 119

Item C.1. Identification of investment.

a. Name of issuer (if any).
Insulet Corp
b. LEI (if any) of issuer. (1)
549300TZTYD2PYN92D43
c. Title of the issue or description of the investment.
Insulet Corp
d. CUSIP (if any).
45784P101
At least one of the following other identifiers:
- ISIN
US45784P1012

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
8555.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
2728702.80000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.466875251485

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 120

Item C.1. Identification of investment.

a. Name of issuer (if any).
Align Technology Inc
b. LEI (if any) of issuer. (1)
549300N5YSE0U3LCP840
c. Title of the issue or description of the investment.
Align Technology Inc
d. CUSIP (if any).
016255101
At least one of the following other identifiers:
- ISIN
US0162551016

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
3960.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1323194.40000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.226395750487

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 121

Item C.1. Identification of investment.

a. Name of issuer (if any).
Viking Therapeutics Inc
b. LEI (if any) of issuer. (1)
529900IVC72YPFA25M37
c. Title of the issue or description of the investment.
Viking Therapeutics Inc
d. CUSIP (if any).
92686J106
At least one of the following other identifiers:
- ISIN
US92686J1060

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
16970.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
282550.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.048343790223

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 122

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
UNITEDHEALTH GROUP INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960FZUX9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-65.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-1625.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00027803404

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
UnitedHealth Group, Inc.
Title of issue.
UnitedHealth Group, Inc.
At least one of the following other identifiers:
- CUSIP.
91324P102
- ISIN (if CUSIP is not available).
US91324P1021
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
500.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-06
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
41229.47000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 123

Item C.1. Identification of investment.

a. Name of issuer (if any).
Becton Dickinson & Co
b. LEI (if any) of issuer. (1)
ICE2EP6D98PQUILVRZ91
c. Title of the issue or description of the investment.
Becton Dickinson & Co
d. CUSIP (if any).
075887109
At least one of the following other identifiers:
- ISIN
US0758871091

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
36070.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
8928767.80000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
1.527693199889

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 124

Item C.1. Identification of investment.

a. Name of issuer (if any).
JEFFERIES LLC
b. LEI (if any) of issuer. (1)
58PU97L1C0WSRCWADL48
c. Title of the issue or description of the investment.
MAY23 ALC US C @ 68.5
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYF2EY75
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-136.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-52766.64000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00902825999

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1JEFFERIES LLC58PU97L1C0WSRCWADL48

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Alcon, Inc.
Title of issue.
Alcon, Inc.
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
CH0432492467
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
68.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-01
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-37429.92000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 125

Item C.1. Identification of investment.

a. Name of issuer (if any).
Penumbra Inc
b. LEI (if any) of issuer. (1)
549300RGE06P3ECANU72
c. Title of the issue or description of the investment.
Penumbra Inc
d. CUSIP (if any).
70975L107
At least one of the following other identifiers:
- ISIN
US70975L1070

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
21510.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
5994621.90000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
1.025667070493

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 126

Item C.1. Identification of investment.

a. Name of issuer (if any).
REVOLUTION Medicines Inc
b. LEI (if any) of issuer. (1)
549300JU3X0LBCQ65892
c. Title of the issue or description of the investment.
REVOLUTION Medicines Inc
d. CUSIP (if any).
76155X100
At least one of the following other identifiers:
- ISIN
US76155X1000

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
18874.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
408810.84000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.069946666135

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 127

Item C.1. Identification of investment.

a. Name of issuer (if any).
IQVIA Holdings Inc
b. LEI (if any) of issuer. (1)
549300W3R20NM4KQPH86
c. Title of the issue or description of the investment.
IQVIA Holdings Inc
d. CUSIP (if any).
46266C105
At least one of the following other identifiers:
- ISIN
US46266C1053

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
26058.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
5182675.62000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.886744787103

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 128

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
RHYTHM PHARMACEUTICALS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9619PB58
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-32.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-4160.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00071176716

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Rhythm Pharmaceuticals, Inc.
Title of issue.
Rhythm Pharmaceuticals, Inc.
At least one of the following other identifiers:
- CUSIP.
76243J105
- ISIN (if CUSIP is not available).
US76243J1051
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
20.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-627.39000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 129

Item C.1. Identification of investment.

a. Name of issuer (if any).
NOMURA SECURITIES INTERNATIONAL INC
b. LEI (if any) of issuer. (1)
OXTKY6Q8X53C9ILVV871
c. Title of the issue or description of the investment.
AVTR US FLEX
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYDVXMR5
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-75.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-245.48000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00004200110

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1NOMURA SECURITIES INTERNATIONAL INCOXTKY6Q8X53C9ILVV871

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Avantor, Inc.
Title of issue.
Avantor, Inc.
At least one of the following other identifiers:
- CUSIP.
05352A100
- ISIN (if CUSIP is not available).
US05352A1007
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
25.29000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
6412.18000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 130

Item C.1. Identification of investment.

a. Name of issuer (if any).
Moderna Inc
b. LEI (if any) of issuer. (1)
549300EI6OKH5K5Q2G38
c. Title of the issue or description of the investment.
Moderna Inc
d. CUSIP (if any).
60770K107
At least one of the following other identifiers:
- ISIN
US60770K1079

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
28938.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
4444298.04000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.760409951974

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 131

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
INTUITIVE SURGICAL INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960YBKJ3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-38.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-22610.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00386852296

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Intuitive Surgical, Inc.
Title of issue.
Intuitive Surgical, Inc.
At least one of the following other identifiers:
- CUSIP.
46120E602
- ISIN (if CUSIP is not available).
US46120E6023
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
265.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
2052.60000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 132

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
BECTON DICKINSON + CO
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960Y4ZZ7
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-105.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-67200.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01149777722

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Becton Dickinson & Co.
Title of issue.
Becton Dickinson & Co.
At least one of the following other identifiers:
- CUSIP.
075887109
- ISIN (if CUSIP is not available).
US0758871091
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
245.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-32784.33000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 133

Item C.1. Identification of investment.

a. Name of issuer (if any).
JP MORGAN CHASE BANK
b. LEI (if any) of issuer. (1)
7H6GLXDRUGQFU57RNE97
c. Title of the issue or description of the investment.
APR23 BLCO US C @ 18.35
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYEECT67
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-7300.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-2670.71000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00045695280

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1JP MORGAN CHASE BANK7H6GLXDRUGQFU57RNE97

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Bausch & Lomb Corp.
Title of issue.
Bausch & Lomb Corp.
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
CA0717051076
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
18.35000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-24
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
5533.03000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 134

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
BAXTER INTERNATIONAL INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960PRHQ6
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-53.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-3180.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00054409124

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Baxter International, Inc.
Title of issue.
Baxter International, Inc.
At least one of the following other identifiers:
- CUSIP.
071813109
- ISIN (if CUSIP is not available).
US0718131099
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
41.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-14
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
93.83000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 135

Item C.1. Identification of investment.

a. Name of issuer (if any).
Stryker Corp
b. LEI (if any) of issuer. (1)
5493002F0SC4JTBU5137
c. Title of the issue or description of the investment.
Stryker Corp
d. CUSIP (if any).
863667101
At least one of the following other identifiers:
- ISIN
US8636671013

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
65135.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
18594088.45000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
3.181409027481

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 136

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
APELLIS PHARMACEUTICALS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95TZ7VR9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-44.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-16060.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00274783187

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Apellis Pharmaceuticals, Inc.
Title of issue.
Apellis Pharmaceuticals, Inc.
At least one of the following other identifiers:
- CUSIP.
03753U106
- ISIN (if CUSIP is not available).
US03753U1060
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
65.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
15491.97000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 137

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
INTUITIVE SURGICAL INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9601V9U3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-58.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-89900.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01538169899

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Intuitive Surgical, Inc.
Title of issue.
Intuitive Surgical, Inc.
At least one of the following other identifiers:
- CUSIP.
46120E602
- ISIN (if CUSIP is not available).
US46120E6023
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
240.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-03-31
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-61240.36000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 138

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
PROMETHEUS BIOSCIENCES INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95XXEZ77
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-13.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-6825.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00116774299

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Prometheus Biosciences, Inc.
Title of issue.
Prometheus Biosciences, Inc.
At least one of the following other identifiers:
- CUSIP.
74349U108
- ISIN (if CUSIP is not available).
US74349U1088
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
125.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
5365.92000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 139

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
DEXCOM INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9605KJS7
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-109.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-24252.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00414955122

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Dexcom, Inc.
Title of issue.
Dexcom, Inc.
At least one of the following other identifiers:
- CUSIP.
252131107
- ISIN (if CUSIP is not available).
US2521311074
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
120.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
26188.36000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 140

Item C.1. Identification of investment.

a. Name of issuer (if any).
JANE STREET EXECUTION SERVICES, LLC
b. LEI (if any) of issuer. (1)
549300HXJLXCPDWAH070
c. Title of the issue or description of the investment.
ZBH US FLEX
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYDZ8G36
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-28.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-8030.62000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00137402201

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1JANE STREET EXECUTION SERVICES, LLC549300HXJLXCPDWAH070

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Zimmer Biomet Holdings, Inc.
Title of issue.
Zimmer Biomet Holdings, Inc.
At least one of the following other identifiers:
- CUSIP.
98956P102
- ISIN (if CUSIP is not available).
US98956P1021
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
128.33000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
1902.74000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 141

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
BLUEPRINT MEDICINES CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95W92WR1
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-50.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-13125.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00224565961

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Blueprint Medicines Corp.
Title of issue.
Blueprint Medicines Corp.
At least one of the following other identifiers:
- CUSIP.
09627Y109
- ISIN (if CUSIP is not available).
US09627Y1091
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
50.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-486.56000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 142

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MEDTRONIC PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95V1L6T4
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-75.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-7125.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00121907236

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Medtronic PLC
Title of issue.
Medtronic PLC
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
IE00BTN1Y115
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
85.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
285.06000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 143

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
BAUSCH + LOMB CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95V03KN2
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-55.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-5912.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00101161618

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
CANADA (FEDERAL LEVEL)
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Bausch & Lomb Corp.
Title of issue.
Bausch & Lomb Corp.
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
CA0717051076
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
17.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-2845.13000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 144

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ABBVIE INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95001V51
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-201.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-87435.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01495994272

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
AbbVie, Inc.
Title of issue.
AbbVie, Inc.
At least one of the following other identifiers:
- CUSIP.
00287Y109
- ISIN (if CUSIP is not available).
US00287Y1091
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
155.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-03-31
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-54718.80000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 145

Item C.1. Identification of investment.

a. Name of issuer (if any).
AstraZeneca PLC
b. LEI (if any) of issuer. (1)
PY6ZZQWO2IZFZC3IOL08
c. Title of the issue or description of the investment.
AstraZeneca PLC
d. CUSIP (if any).
046353108
At least one of the following other identifiers:
- ISIN
US0463531089

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
24607.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1707971.87000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.292230358079

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 146

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
BOSTON SCIENTIFIC CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z96057Q09
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-767.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-118885.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.02034097090

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Boston Scientific Corp.
Title of issue.
Boston Scientific Corp.
At least one of the following other identifiers:
- CUSIP.
101137107
- ISIN (if CUSIP is not available).
US1011371077
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
49.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-48880.75000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 147

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
PFIZER INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960QN066
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-83.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-4772.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00081656461

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Pfizer, Inc.
Title of issue.
Pfizer, Inc.
At least one of the following other identifiers:
- CUSIP.
717081103
- ISIN (if CUSIP is not available).
US7170811035
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
41.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-14
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
1516.43000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 148

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ELEVANCE HEALTH INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960Y98L7
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-61.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-30042.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00514020791

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Elevance Health, Inc.
Title of issue.
Elevance Health, Inc.
At least one of the following other identifiers:
- CUSIP.
036752103
- ISIN (if CUSIP is not available).
US0367521038
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
480.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
23026.99000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 149

Item C.1. Identification of investment.

a. Name of issuer (if any).
Cigna Group/The
b. LEI (if any) of issuer. (1)
549300VIWYMSIGT1U456
c. Title of the issue or description of the investment.
Cigna Group/The
d. CUSIP (if any).
125523100
At least one of the following other identifiers:
- ISIN
US1255231003

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
13289.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
3395738.17000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.581003586061

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 150

Item C.1. Identification of investment.

a. Name of issuer (if any).
Structure Therapeutics Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Structure Therapeutics Inc
d. CUSIP (if any).
86366E106
At least one of the following other identifiers:
- ISIN
US86366E1064

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
13208.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
314218.32000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.053762086941

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
CAYMAN ISLANDS
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 151

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ENVISTA HOLDINGS CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z96075JV1
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-80.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-23200.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00396947070

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Envista Holdings Corp.
Title of issue.
Envista Holdings Corp.
At least one of the following other identifiers:
- CUSIP.
29415F104
- ISIN (if CUSIP is not available).
US29415F1049
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
39.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-13561.57000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 152

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ARVINAS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95U2RKG4
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-26.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-12480.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00213530148

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Arvinas, Inc.
Title of issue.
Arvinas, Inc.
At least one of the following other identifiers:
- CUSIP.
04335A105
- ISIN (if CUSIP is not available).
US04335A1051
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
40.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-7553.71000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 153

Item C.1. Identification of investment.

a. Name of issuer (if any).
Enanta Pharmaceuticals Inc
b. LEI (if any) of issuer. (1)
529900SSN4DODDQSN594
c. Title of the issue or description of the investment.
Enanta Pharmaceuticals Inc
d. CUSIP (if any).
29251M106
At least one of the following other identifiers:
- ISIN
US29251M1062

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
3150.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
127386.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.021795473946

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 154

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MEDTRONIC PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960YFPB6
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-53.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-17278.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00295622908

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Medtronic PLC
Title of issue.
Medtronic PLC
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
IE00BTN1Y115
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
78.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-3881.25000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 155

Item C.1. Identification of investment.

a. Name of issuer (if any).
Illumina Inc
b. LEI (if any) of issuer. (1)
SQ95QG8SR5Q56LSNF682
c. Title of the issue or description of the investment.
Illumina Inc
d. CUSIP (if any).
452327109
At least one of the following other identifiers:
- ISIN
US4523271090

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
12680.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
2948734.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.504522122311

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
i. If Yes, provide the value of the securities on loan.
1046475.00000000
Schedule of Portfolio Investments Record: 156

Item C.1. Identification of investment.

a. Name of issuer (if any).
CITIBANK NA
b. LEI (if any) of issuer. (1)
E57ODZWZ7FF32TWEFA76
c. Title of the issue or description of the investment.
APR23 ZBH US C @ 126.959
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYFDM411
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-2700.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-12425.32000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00212594585

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1CITIBANK NAE57ODZWZ7FF32TWEFA76

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Zimmer Biomet Holdings, Inc.
Title of issue.
Zimmer Biomet Holdings, Inc.
At least one of the following other identifiers:
- CUSIP.
98956P102
- ISIN (if CUSIP is not available).
US98956P1021
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
126.95900000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-27
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-4369.87000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 157

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MCKESSON CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9601ZAF5
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-32.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-2400.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00041063490

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
McKesson Corp.
Title of issue.
McKesson Corp.
At least one of the following other identifiers:
- CUSIP.
58155Q103
- ISIN (if CUSIP is not available).
US58155Q1031
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
370.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-03-31
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
12947.13000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 158

Item C.1. Identification of investment.

a. Name of issuer (if any).
Mirati Therapeutics Inc
b. LEI (if any) of issuer. (1)
529900GYRW59IDQV6N54
c. Title of the issue or description of the investment.
Mirati Therapeutics Inc
d. CUSIP (if any).
60468T105
At least one of the following other identifiers:
- ISIN
US60468T1051

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
15380.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
571828.40000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.097838624293

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 159

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
THERMO FISHER SCIENTIFIC INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z96029WS0
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-101.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-161600.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.02764941665

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Thermo Fisher Scientific, Inc.
Title of issue.
Thermo Fisher Scientific, Inc.
At least one of the following other identifiers:
- CUSIP.
883556102
- ISIN (if CUSIP is not available).
US8835561023
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
560.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-03-31
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-25478.26000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 160

Item C.1. Identification of investment.

a. Name of issuer (if any).
Orchestra BioMed Holdings Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Orchestra BioMed Holdings Inc
d. CUSIP (if any).
68572M106
At least one of the following other identifiers:
- ISIN
US68572M1062

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
13696.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
268030.72000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.045859486715

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
i. If Yes, provide the value of the securities on loan.
25441.00000000
Schedule of Portfolio Investments Record: 161

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
PENUMBRA INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95V4KXX4
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-81.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-122715.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.02099627577

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Penumbra, Inc.
Title of issue.
Penumbra, Inc.
At least one of the following other identifiers:
- CUSIP.
70975L107
- ISIN (if CUSIP is not available).
US70975L1070
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
270.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-34606.26000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 162

Item C.1. Identification of investment.

a. Name of issuer (if any).
Cerevel Therapeutics Holdings Inc
b. LEI (if any) of issuer. (1)
254900RJNIRS9COSQR41
c. Title of the issue or description of the investment.
Cerevel Therapeutics Holdings Inc
d. CUSIP (if any).
15678U128
At least one of the following other identifiers:
- ISIN
US15678U1280

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
16785.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
409386.15000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.070045100454

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 163

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
STERIS PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9607NQ51
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-31.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-8447.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00144534930

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
STERIS PLC
Title of issue.
STERIS PLC
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
IE00BFY8C754
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
200.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
4180.69000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 164

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
NOVOCURE LTD
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95QNABZ5
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-51.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-3570.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00061081941

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
JERSEY
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Novocure Ltd.
Title of issue.
Novocure Ltd.
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
JE00BYSS4X48
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
100.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
14660.29000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 165

Item C.1. Identification of investment.

a. Name of issuer (if any).
Affinivax Inc.,
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Affinivax Inc.,
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRY5YZ4R4
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
6331.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
83126.03000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.014222687117

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 166

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
KRYSTAL BIOTECH INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9606K9Z1
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-6.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-2520.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00043116664

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Krystal Biotech, Inc.
Title of issue.
Krystal Biotech, Inc.
At least one of the following other identifiers:
- CUSIP.
501147102
- ISIN (if CUSIP is not available).
US5011471027
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
85.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-1528.92000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 167

Item C.1. Identification of investment.

a. Name of issuer (if any).
Guardant Health Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Guardant Health Inc
d. CUSIP (if any).
40131M109
At least one of the following other identifiers:
- ISIN
US40131M1099

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
11675.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
273662.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.046822986758

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 168

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MEDTRONIC PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95ZJCYQ1
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-126.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-882.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00015090832

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Medtronic PLC
Title of issue.
Medtronic PLC
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
IE00BTN1Y115
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
87.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
33304.35000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 169

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
IONIS PHARMACEUTICALS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9618NP67
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-29.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-1377.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00023568732

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Ionis Pharmaceuticals, Inc.
Title of issue.
Ionis Pharmaceuticals, Inc.
At least one of the following other identifiers:
- CUSIP.
462222100
- ISIN (if CUSIP is not available).
US4622221004
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
40.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
733.85000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 170

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
RESMED INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95U1N142
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-33.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-14850.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00254080344

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
ResMed, Inc.
Title of issue.
ResMed, Inc.
At least one of the following other identifiers:
- CUSIP.
761152107
- ISIN (if CUSIP is not available).
US7611521078
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
220.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
7669.34000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 171

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
AMGEN INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95TZA3F9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-129.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-39990.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00684220403

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Amgen, Inc.
Title of issue.
Amgen, Inc.
At least one of the following other identifiers:
- CUSIP.
031162100
- ISIN (if CUSIP is not available).
US0311621009
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
245.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-10607.79000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 172

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ROCKET PHARMACEUTICALS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95U1PFG5
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-65.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-975.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00016682042

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Rocket Pharmaceuticals, Inc.
Title of issue.
Rocket Pharmaceuticals, Inc.
At least one of the following other identifiers:
- CUSIP.
77313F106
- ISIN (if CUSIP is not available).
US77313F1066
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
22.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
6167.10000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 173

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
OMNICELL INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9604PF44
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-12.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-3960.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00067754758

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Omnicell, Inc.
Title of issue.
Omnicell, Inc.
At least one of the following other identifiers:
- CUSIP.
68213N109
- ISIN (if CUSIP is not available).
US68213N1090
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
60.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-1286.82000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 174

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
AGILENT TECHNOLOGIES INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95UZYH69
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-63.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-8820.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00150908326

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Agilent Technologies, Inc.
Title of issue.
Agilent Technologies, Inc.
At least one of the following other identifiers:
- CUSIP.
00846U101
- ISIN (if CUSIP is not available).
US00846U1016
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
150.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
9624.42000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 175

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
BAXTER INTERNATIONAL INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960Y5FU7
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-194.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-28615.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00489596570

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Baxter International, Inc.
Title of issue.
Baxter International, Inc.
At least one of the following other identifiers:
- CUSIP.
071813109
- ISIN (if CUSIP is not available).
US0718131099
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
41.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-1887.66000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 176

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
AMERISOURCEBERGEN CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z96019K70
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-4.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-300.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00005132936

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
AmerisourceBergen Corp.
Title of issue.
AmerisourceBergen Corp.
At least one of the following other identifiers:
- CUSIP.
03073E105
- ISIN (if CUSIP is not available).
US03073E1055
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
165.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-03-31
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
494.54000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 177

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
AMERISOURCEBERGEN CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960Y44L2
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-23.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-15870.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00271532328

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
AmerisourceBergen Corp.
Title of issue.
AmerisourceBergen Corp.
At least one of the following other identifiers:
- CUSIP.
03073E105
- ISIN (if CUSIP is not available).
US03073E1055
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
155.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-9468.88000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 178

Item C.1. Identification of investment.

a. Name of issuer (if any).
Incyte Corp
b. LEI (if any) of issuer. (1)
549300Z4WN6JVZ3T4680
c. Title of the issue or description of the investment.
Incyte Corp
d. CUSIP (if any).
45337C102
At least one of the following other identifiers:
- ISIN
US45337C1027

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
33358.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
2410782.66000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.412479791006

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 179

Item C.1. Identification of investment.

a. Name of issuer (if any).
Krystal Biotech Inc
b. LEI (if any) of issuer. (1)
549300YONUY68210OE41
c. Title of the issue or description of the investment.
Krystal Biotech Inc
d. CUSIP (if any).
501147102
At least one of the following other identifiers:
- ISIN
US5011471027

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
3135.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
250988.10000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.042943530642

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 180

Item C.1. Identification of investment.

a. Name of issuer (if any).
JP MORGAN CHASE BANK
b. LEI (if any) of issuer. (1)
7H6GLXDRUGQFU57RNE97
c. Title of the issue or description of the investment.
APR23 4568 JP C @ 4374.24
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYDWXQE9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-22500.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
Japan Yen
e. Value. (4)
-77039.02000000
f. Exchange rate.
132.77500000
g. Percentage value compared to net assets of the Fund.
-0.01318121263

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1JP MORGAN CHASE BANK7H6GLXDRUGQFU57RNE97

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Daiichi Sankyo Co. Ltd.
Title of issue.
Daiichi Sankyo Co. Ltd.
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
JP3475350009
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
4374.24000000
vi. Exercise Price Currency Code
Japan Yen
vii. Expiration date.
2023-04-04
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-58154.22000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 181

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
EXACT SCIENCES CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9601MSE8
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-35.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-437.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00007485532

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Exact Sciences Corp.
Title of issue.
Exact Sciences Corp.
At least one of the following other identifiers:
- CUSIP.
30063P105
- ISIN (if CUSIP is not available).
US30063P1057
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
68.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-03-31
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
3903.19000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 182

Item C.1. Identification of investment.

a. Name of issuer (if any).
Nautilus Biotechnology Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Nautilus Biotechnology Inc
d. CUSIP (if any).
63909J108
At least one of the following other identifiers:
- ISIN
US63909J1088

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
16560.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
45871.20000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.007848464858

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 183

Item C.1. Identification of investment.

a. Name of issuer (if any).
AstraZeneca PLC
b. LEI (if any) of issuer. (1)
PY6ZZQWO2IZFZC3IOL08
c. Title of the issue or description of the investment.
AstraZeneca PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- ISIN
GB0009895292

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
41126.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United Kingdom Pound
e. Value. (4)
5698182.90000000
f. Exchange rate.
0.81063600
g. Percentage value compared to net assets of the Fund.
0.974946987428

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 184

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
BIOMARIN PHARMACEUTICAL INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95PU6S31
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-52.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-3640.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00062279626

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
BioMarin Pharmaceutical, Inc.
Title of issue.
BioMarin Pharmaceutical, Inc.
At least one of the following other identifiers:
- CUSIP.
09061G101
- ISIN (if CUSIP is not available).
US09061G1013
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
115.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
13143.70000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 185

Item C.1. Identification of investment.

a. Name of issuer (if any).
Intuitive Surgical Inc
b. LEI (if any) of issuer. (1)
54930052SRG011710797
c. Title of the issue or description of the investment.
Intuitive Surgical Inc
d. CUSIP (if any).
46120E602
At least one of the following other identifiers:
- ISIN
US46120E6023

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
56844.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
14521936.68000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
2.484672511615

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 186

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
CENTENE CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960G75E0
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-111.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-1665.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00028487796

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Centene Corp.
Title of issue.
Centene Corp.
At least one of the following other identifiers:
- CUSIP.
15135B101
- ISIN (if CUSIP is not available).
US15135B1017
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
70.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-06
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
20803.14000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 187

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
OMNICELL INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95UZPAV0
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-12.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-4620.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00079047218

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Omnicell, Inc.
Title of issue.
Omnicell, Inc.
At least one of the following other identifiers:
- CUSIP.
68213N109
- ISIN (if CUSIP is not available).
US68213N1090
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
60.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-2246.77000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 188

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MODERNA INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960GFHB5
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-72.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-68220.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01167229705

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Moderna, Inc.
Title of issue.
Moderna, Inc.
At least one of the following other identifiers:
- CUSIP.
60770K107
- ISIN (if CUSIP is not available).
US60770K1079
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
145.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-06
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-31983.79000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 189

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ULTRAGENYX PHARMACEUTICAL INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9607DLJ8
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-23.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-1092.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00018692442

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Ultragenyx Pharmaceutical, Inc.
Title of issue.
Ultragenyx Pharmaceutical, Inc.
At least one of the following other identifiers:
- CUSIP.
90400D108
- ISIN (if CUSIP is not available).
US90400D1081
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
50.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
11306.79000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 190

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
IDEXX LABORATORIES INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9618L1Z3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-27.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-59670.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01020941022

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
IDEXX Laboratories, Inc.
Title of issue.
IDEXX Laboratories, Inc.
At least one of the following other identifiers:
- CUSIP.
45168D104
- ISIN (if CUSIP is not available).
US45168D1046
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
510.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-21216.74000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 191

Item C.1. Identification of investment.

a. Name of issuer (if any).
ICON PLC
b. LEI (if any) of issuer. (1)
6354008SRQGEMC4XFI67
c. Title of the issue or description of the investment.
ICON PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- ISIN
IE0005711209

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
8210.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1753573.90000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.300032768523

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 192

Item C.1. Identification of investment.

a. Name of issuer (if any).
Amgen Inc
b. LEI (if any) of issuer. (1)
62QBXGPJ34PQ72Z12S66
c. Title of the issue or description of the investment.
Amgen Inc
d. CUSIP (if any).
031162100
At least one of the following other identifiers:
- ISIN
US0311621009

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
67355.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
16283071.25000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
2.785998894712

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 193

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
CATALENT INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95U2X388
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-38.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-5415.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00092649499

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Catalent, Inc.
Title of issue.
Catalent, Inc.
At least one of the following other identifiers:
- CUSIP.
148806102
- ISIN (if CUSIP is not available).
US1488061029
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
75.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
10079.94000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 194

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
PROMETHEUS BIOSCIENCES INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9607BRS6
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-13.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-4550.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00077849533

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Prometheus Biosciences, Inc.
Title of issue.
Prometheus Biosciences, Inc.
At least one of the following other identifiers:
- CUSIP.
74349U108
- ISIN (if CUSIP is not available).
US74349U1088
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
145.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
2682.32000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 195

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ASTRAZENECA PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960RCXB2
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-93.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-26133.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00447130077

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
AstraZeneca PLC
Title of issue.
AstraZeneca PLC
At least one of the following other identifiers:
- CUSIP.
046353108
- ISIN (if CUSIP is not available).
US0463531089
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
67.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-14
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-18539.72000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 196

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
JOHNSON + JOHNSON
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960GCUL5
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-18.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-2097.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00035879224

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Johnson & Johnson
Title of issue.
Johnson & Johnson
At least one of the following other identifiers:
- CUSIP.
478160104
- ISIN (if CUSIP is not available).
US4781601046
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
155.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-06
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
1538.35000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 197

Item C.1. Identification of investment.

a. Name of issuer (if any).
Karuna Therapeutics Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Karuna Therapeutics Inc
d. CUSIP (if any).
48576A100
At least one of the following other identifiers:
- ISIN
US48576A1007

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
1825.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
331493.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.056717747986

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 198

Item C.1. Identification of investment.

a. Name of issuer (if any).
Immuneering Corp
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Immuneering Corp
d. CUSIP (if any).
45254E107
At least one of the following other identifiers:
- ISIN
US45254E1073

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
14456.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
140367.76000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.024016625500

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
i. If Yes, provide the value of the securities on loan.
19420.00000000
Schedule of Portfolio Investments Record: 199

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
AVANTOR INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95V30PB6
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-149.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-10430.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00178455083

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Avantor, Inc.
Title of issue.
Avantor, Inc.
At least one of the following other identifiers:
- CUSIP.
05352A100
- ISIN (if CUSIP is not available).
US05352A1007
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
22.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-164.00000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 200

Item C.1. Identification of investment.

a. Name of issuer (if any).
Immunocore Holdings PLC
b. LEI (if any) of issuer. (1)
213800IUE3DFS84BVN18
c. Title of the issue or description of the investment.
Immunocore Holdings PLC
d. CUSIP (if any).
45258D105
At least one of the following other identifiers:
- ISIN
US45258D1054

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
9668.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
477985.92000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.081782375349

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
i. If Yes, provide the value of the securities on loan.
103824.00000000
Schedule of Portfolio Investments Record: 201

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ILLUMINA INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9606B9G3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-48.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-53040.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00907503130

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Illumina, Inc.
Title of issue.
Illumina, Inc.
At least one of the following other identifiers:
- CUSIP.
452327109
- ISIN (if CUSIP is not available).
US4523271090
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
230.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-29337.18000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 202

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MODERNA INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960YEBP3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-5.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-1240.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00021216136

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Moderna, Inc.
Title of issue.
Moderna, Inc.
At least one of the following other identifiers:
- CUSIP.
60770K107
- ISIN (if CUSIP is not available).
US60770K1079
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
170.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
1036.35000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 203

Item C.1. Identification of investment.

a. Name of issuer (if any).
Goldfinch Bio, Inc. SERIES B
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Goldfinch Bio, Inc. SERIES B
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRW5236Q2
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
190000.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
62700.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.010727836783

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 204

Item C.1. Identification of investment.

a. Name of issuer (if any).
JP MORGAN CHASE BANK
b. LEI (if any) of issuer. (1)
7H6GLXDRUGQFU57RNE97
c. Title of the issue or description of the investment.
APR23 SAN FP C @ 91.735
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYFJD084
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-4700.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
Euro Member Countries
e. Value. (4)
-46230.13000000
f. Exchange rate.
0.92208400
g. Percentage value compared to net assets of the Fund.
-0.00790987701

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1JP MORGAN CHASE BANK7H6GLXDRUGQFU57RNE97

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Sanofi
Title of issue.
Sanofi
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
FR0000120578
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
91.73500000
vi. Exercise Price Currency Code
Euro Member Countries
vii. Expiration date.
2023-04-27
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-35978.67000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 205

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MODERNA INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9500D2E8
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-22.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-154.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00002634907

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Moderna, Inc.
Title of issue.
Moderna, Inc.
At least one of the following other identifiers:
- CUSIP.
60770K107
- ISIN (if CUSIP is not available).
US60770K1079
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
160.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-03-31
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
4163.05000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 206

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
VERTEX PHARMACEUTICALS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960YQAF9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-70.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-65800.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01125824019

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Vertex Pharmaceuticals, Inc.
Title of issue.
Vertex Pharmaceuticals, Inc.
At least one of the following other identifiers:
- CUSIP.
92532F100
- ISIN (if CUSIP is not available).
US92532F1003
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
315.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-10733.67000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 207

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MEDTRONIC PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960GF5C6
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-65.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-617.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00010565293

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Medtronic PLC
Title of issue.
Medtronic PLC
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
IE00BTN1Y115
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
83.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-06
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
13537.49000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 208

Item C.1. Identification of investment.

a. Name of issuer (if any).
Quanta Dialysis Technologies Ltd SERIES D
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Quanta Dialysis Technologies Ltd SERIES D
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRWM20K77
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
4243029.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United Kingdom Pound
e. Value. (4)
366393.83000000
f. Exchange rate.
0.81063600
g. Percentage value compared to net assets of the Fund.
0.062689205846

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 209

Item C.1. Identification of investment.

a. Name of issuer (if any).
Abbott Laboratories
b. LEI (if any) of issuer. (1)
HQD377W2YR662HK5JX27
c. Title of the issue or description of the investment.
Abbott Laboratories
d. CUSIP (if any).
002824100
At least one of the following other identifiers:
- ISIN
US0028241000

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
129731.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
13136561.06000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
2.247637686500

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 210

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
INSULET CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960701G4
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-14.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-12810.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00219176378

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Insulet Corp.
Title of issue.
Insulet Corp.
At least one of the following other identifiers:
- CUSIP.
45784P101
- ISIN (if CUSIP is not available).
US45784P1012
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
320.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
3118.42000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 211

Item C.1. Identification of investment.

a. Name of issuer (if any).
MORGAN STANLEY & CO. INTERNATIONAL
b. LEI (if any) of issuer. (1)
4PQUHN3JPFGFNF3BB653
c. Title of the issue or description of the investment.
APR23 ROG SW C @ 288.6758
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYDZFU34
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-1300.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
Switzerland Franc
e. Value. (4)
-9.49000000
f. Exchange rate.
0.91495000
g. Percentage value compared to net assets of the Fund.
-0.00000162371

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1MORGAN STANLEY & CO. INTERNATIONAL4PQUHN3JPFGFNF3BB653

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Roche Holding AG
Title of issue.
Roche Holding AG
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
CH0012032048
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
288.67580000
vi. Exercise Price Currency Code
Switzerland Franc
vii. Expiration date.
2023-04-11
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
2255.89000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 212

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ELI LILLY + CO
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9601XPX5
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-115.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-95737.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01638048283

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Eli Lilly & Co.
Title of issue.
Eli Lilly & Co.
At least one of the following other identifiers:
- CUSIP.
532457108
- ISIN (if CUSIP is not available).
US5324571083
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
335.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-03-31
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-59672.46000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 213

Item C.1. Identification of investment.

a. Name of issuer (if any).
Exo Imaging, Inc. SERIES C
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Exo Imaging, Inc. SERIES C
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRWNKD2Y8
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
101741.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
285892.21000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.048915549704

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 214

Item C.1. Identification of investment.

a. Name of issuer (if any).
Blueprint Medicines Corp
b. LEI (if any) of issuer. (1)
5299004CC60O9T5HVM83
c. Title of the issue or description of the investment.
Blueprint Medicines Corp
d. CUSIP (if any).
09627Y109
At least one of the following other identifiers:
- ISIN
US09627Y1091

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
26725.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1202357.75000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.205720856410

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 215

Item C.1. Identification of investment.

a. Name of issuer (if any).
GE HealthCare Technologies Inc
b. LEI (if any) of issuer. (1)
549300OI9J7XOWZMUN85
c. Title of the issue or description of the investment.
GE HealthCare Technologies Inc
d. CUSIP (if any).
36266G107
At least one of the following other identifiers:
- ISIN
US36266G1076

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
68490.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
5618234.70000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.961268020271

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 216

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
UNITEDHEALTH GROUP INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960Y0GN3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-209.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-173470.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.02968034843

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
UnitedHealth Group, Inc.
Title of issue.
UnitedHealth Group, Inc.
At least one of the following other identifiers:
- CUSIP.
91324P102
- ISIN (if CUSIP is not available).
US91324P1021
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
485.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-3602.24000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 217

Item C.1. Identification of investment.

a. Name of issuer (if any).
Morphic Holding Inc
b. LEI (if any) of issuer. (1)
549300RWWOUFLHTY1224
c. Title of the issue or description of the investment.
Morphic Holding Inc
d. CUSIP (if any).
61775R105
At least one of the following other identifiers:
- ISIN
US61775R1059

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
7120.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
267996.80000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.045853683075

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 218

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
AMERISOURCEBERGEN CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z961DDQ54
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-81.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-38070.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00651369611

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
AmerisourceBergen Corp.
Title of issue.
AmerisourceBergen Corp.
At least one of the following other identifiers:
- CUSIP.
03073E105
- ISIN (if CUSIP is not available).
US03073E1055
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
157.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-13343.25000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 219

Item C.1. Identification of investment.

a. Name of issuer (if any).
CITIBANK NA
b. LEI (if any) of issuer. (1)
E57ODZWZ7FF32TWEFA76
c. Title of the issue or description of the investment.
MAY23 4568 JP C @ 4526.08
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYF65Z38
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-10400.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
Japan Yen
e. Value. (4)
-32367.21000000
f. Exchange rate.
132.77500000
g. Percentage value compared to net assets of the Fund.
-0.00553796086

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1CITIBANK NAE57ODZWZ7FF32TWEFA76

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Daiichi Sankyo Co. Ltd.
Title of issue.
Daiichi Sankyo Co. Ltd.
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
JP3475350009
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
4526.08000000
vi. Exercise Price Currency Code
Japan Yen
vii. Expiration date.
2023-05-02
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-21922.42000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 220

Item C.1. Identification of investment.

a. Name of issuer (if any).
Prothena Corp PLC
b. LEI (if any) of issuer. (1)
5299009ZXQ8NIIJ8OL30
c. Title of the issue or description of the investment.
Prothena Corp PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- ISIN
IE00B91XRN20

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
8734.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
423336.98000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.072432057826

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 221

Item C.1. Identification of investment.

a. Name of issuer (if any).
Nuvalent Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Nuvalent Inc
d. CUSIP (if any).
670703107
At least one of the following other identifiers:
- ISIN
US6707031075

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
11178.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
291634.02000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.049897961195

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 222

Item C.1. Identification of investment.

a. Name of issuer (if any).
Envista Holdings Corp
b. LEI (if any) of issuer. (1)
549300BX623VURJZ5269
c. Title of the issue or description of the investment.
Envista Holdings Corp
d. CUSIP (if any).
29415F104
At least one of the following other identifiers:
- ISIN
US29415F1049

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
21195.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
866451.60000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.148248027835

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 223

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
BOSTON SCIENTIFIC CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95V06FR2
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-767.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-185997.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.03182377706

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Boston Scientific Corp.
Title of issue.
Boston Scientific Corp.
At least one of the following other identifiers:
- CUSIP.
101137107
- ISIN (if CUSIP is not available).
US1011371077
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
49.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-57318.23000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 224

Item C.1. Identification of investment.

a. Name of issuer (if any).
BARCLAYS BANK PLC
b. LEI (if any) of issuer. (1)
G5GSEF7VJP5I7OUK5573
c. Title of the issue or description of the investment.
MAY23 NBIX US C @ 100.466
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYF5JEF5
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-4400.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-19772.24000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00338298825

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1BARCLAYS BANK PLCG5GSEF7VJP5I7OUK5573

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Neurocrine Biosciences, Inc.
Title of issue.
Neurocrine Biosciences, Inc.
At least one of the following other identifiers:
- CUSIP.
64125C109
- ISIN (if CUSIP is not available).
US64125C1099
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
100.46600000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-15
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-7100.24000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 225

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
EDWARDS LIFESCIENCES CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9601MGD3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-53.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-4372.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00074812545

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Edwards Lifesciences Corp.
Title of issue.
Edwards Lifesciences Corp.
At least one of the following other identifiers:
- CUSIP.
28176E108
- ISIN (if CUSIP is not available).
US28176E1082
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
82.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-03-31
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
8306.50000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 226

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
10X GENOMICS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95X3MG81
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-22.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-12100.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00207028429

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
10X Genomics, Inc.
Title of issue.
10X Genomics, Inc.
At least one of the following other identifiers:
- CUSIP.
88025U109
- ISIN (if CUSIP is not available).
US88025U1097
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
55.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-5464.82000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 227

Item C.1. Identification of investment.

a. Name of issuer (if any).
Dexcom Inc
b. LEI (if any) of issuer. (1)
549300YSK3QDSFR5EU59
c. Title of the issue or description of the investment.
Dexcom Inc
d. CUSIP (if any).
252131107
At least one of the following other identifiers:
- ISIN
US2521311074

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
54892.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
6377352.56000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
1.091151473242

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 228

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MASIMO CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z96194Z83
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-16.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-27120.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00464017437

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Masimo Corp.
Title of issue.
Masimo Corp.
At least one of the following other identifiers:
- CUSIP.
574795100
- ISIN (if CUSIP is not available).
US5747951003
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
175.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-11127.32000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 229

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
BRISTOL-MYERS SQUIBB CO
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960Y5DX3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-74.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-11248.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00192450890

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Bristol-Myers Squibb Co.
Title of issue.
Bristol-Myers Squibb Co.
At least one of the following other identifiers:
- CUSIP.
110122108
- ISIN (if CUSIP is not available).
US1101221083
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
69.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-3679.52000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 230

Item C.1. Identification of investment.

a. Name of issuer (if any).
IVERIC bio Inc
b. LEI (if any) of issuer. (1)
549300GZXI59U71XPM70
c. Title of the issue or description of the investment.
IVERIC bio Inc
d. CUSIP (if any).
46583P102
At least one of the following other identifiers:
- ISIN
US46583P1021

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
12230.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
297555.90000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.050911182281

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 231

Item C.1. Identification of investment.

a. Name of issuer (if any).
Pfizer Inc
b. LEI (if any) of issuer. (1)
765LHXWGK1KXCLTFYQ30
c. Title of the issue or description of the investment.
Pfizer Inc
d. CUSIP (if any).
717081103
At least one of the following other identifiers:
- ISIN
US7170811035

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
206621.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
8430136.80000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
1.442378495216

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 232

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MCKESSON CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960QBVN1
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-39.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-38025.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00650599670

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
McKesson Corp.
Title of issue.
McKesson Corp.
At least one of the following other identifiers:
- CUSIP.
58155Q103
- ISIN (if CUSIP is not available).
US58155Q1031
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
350.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-14
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-12174.82000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 233

Item C.1. Identification of investment.

a. Name of issuer (if any).
Sarepta Therapeutics Inc
b. LEI (if any) of issuer. (1)
549300IKDPIED8J8IG21
c. Title of the issue or description of the investment.
Sarepta Therapeutics Inc
d. CUSIP (if any).
803607100
At least one of the following other identifiers:
- ISIN
US8036071004

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
18688.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
2575767.04000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.440708267887

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 234

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
GILEAD SCIENCES INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960GUVM2
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-38.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-5396.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00092324413

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Gilead Sciences, Inc.
Title of issue.
Gilead Sciences, Inc.
At least one of the following other identifiers:
- CUSIP.
375558103
- ISIN (if CUSIP is not available).
US3755581036
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
82.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-06
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
813.82000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 235

Item C.1. Identification of investment.

a. Name of issuer (if any).
JANE STREET EXECUTION SERVICES, LLC
b. LEI (if any) of issuer. (1)
549300HXJLXCPDWAH070
c. Title of the issue or description of the investment.
ZTS US FLEX
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYDZ8ML9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-138.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-16206.17000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00277284125

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1JANE STREET EXECUTION SERVICES, LLC549300HXJLXCPDWAH070

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Zoetis, Inc.
Title of issue.
Zoetis, Inc.
At least one of the following other identifiers:
- CUSIP.
98978V103
- ISIN (if CUSIP is not available).
US98978V1035
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
172.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
92641.72000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 236

Item C.1. Identification of investment.

a. Name of issuer (if any).
Edwards Lifesciences Corp
b. LEI (if any) of issuer. (1)
YA13X31F3V31L8TMPR58
c. Title of the issue or description of the investment.
Edwards Lifesciences Corp
d. CUSIP (if any).
28176E108
At least one of the following other identifiers:
- ISIN
US28176E1082

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
37566.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
3107835.18000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.531743996171

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 237

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
REPLIGEN CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95V25GZ3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-31.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-14260.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00243985570

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Repligen Corp.
Title of issue.
Repligen Corp.
At least one of the following other identifiers:
- CUSIP.
759916109
- ISIN (if CUSIP is not available).
US7599161095
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
190.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
13875.71000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 238

Item C.1. Identification of investment.

a. Name of issuer (if any).
CareMax Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
CareMax Inc
d. CUSIP (if any).
14171W111
At least one of the following other identifiers:
- ISIN
US14171W1119

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
4201.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
2135.79000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.000365429131

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Warrant
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1N/AN/A

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
CareMax Inc
Title of issue.
CareMax Inc
At least one of the following other identifiers:
- CUSIP.
14171W103
- ISIN (if CUSIP is not available).
US14171W1036
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
11.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2026-06-08
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-3837.76000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 239

Item C.1. Identification of investment.

a. Name of issuer (if any).
Biomea Fusion Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Biomea Fusion Inc
d. CUSIP (if any).
09077A106
At least one of the following other identifiers:
- ISIN
US09077A1060

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
17544.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
544039.44000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.093083992279

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 240

Item C.1. Identification of investment.

a. Name of issuer (if any).
Argenx SE
b. LEI (if any) of issuer. (1)
7245009C5FZE6G9ODQ71
c. Title of the issue or description of the investment.
Argenx SE
d. CUSIP (if any).
04016X101
At least one of the following other identifiers:
- ISIN
US04016X1019

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
7121.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
2653142.18000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.453946989944

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
NETHERLANDS
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 241

Item C.1. Identification of investment.

a. Name of issuer (if any).
UBS AG
b. LEI (if any) of issuer. (1)
BFM8T61CT2L1QCEMIK50
c. Title of the issue or description of the investment.
MAY23 ROG SW C @ 258.8327
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYFSNN53
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-1200.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
Switzerland Franc
e. Value. (4)
-9183.04000000
f. Exchange rate.
0.91495000
g. Percentage value compared to net assets of the Fund.
-0.00157119863

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1UBS AGBFM8T61CT2L1QCEMIK50

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Roche Holding AG
Title of issue.
Roche Holding AG
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
CH0012032048
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
258.83270000
vi. Exercise Price Currency Code
Switzerland Franc
vii. Expiration date.
2023-05-16
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-2736.40000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 242

Item C.1. Identification of investment.

a. Name of issuer (if any).
JANE STREET EXECUTION SERVICES, LLC
b. LEI (if any) of issuer. (1)
549300HN4UKV1E2R3U73
c. Title of the issue or description of the investment.
JUN23 ALKS US C @ 29.12
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYF8VKS0
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-22.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-2921.45000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00049985388

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1JANE STREET EXECUTION SERVICES, LLC549300HN4UKV1E2R3U73

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Alkermes PLC
Title of issue.
Alkermes PLC
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
IE00B56GVS15
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
29.12000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-06-06
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-1034.51000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 243

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
RHYTHM PHARMACEUTICALS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95U1K5W2
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-83.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-1452.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00024851966

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Rhythm Pharmaceuticals, Inc.
Title of issue.
Rhythm Pharmaceuticals, Inc.
At least one of the following other identifiers:
- CUSIP.
76243J105
- ISIN (if CUSIP is not available).
US76243J1051
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
30.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
11642.18000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 244

Item C.1. Identification of investment.

a. Name of issuer (if any).
Legend Biotech Corp
b. LEI (if any) of issuer. (1)
254900EIUFZTW136H859
c. Title of the issue or description of the investment.
Legend Biotech Corp
d. CUSIP (if any).
52490G102
At least one of the following other identifiers:
- ISIN
US52490G1022

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
14146.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
682120.12000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.116709303251

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
CAYMAN ISLANDS
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 245

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
KARUNA THERAPEUTICS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95V1GF65
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-6.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-780.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00013345634

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Karuna Therapeutics, Inc.
Title of issue.
Karuna Therapeutics, Inc.
At least one of the following other identifiers:
- CUSIP.
48576A100
- ISIN (if CUSIP is not available).
US48576A1007
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
220.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
2369.00000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 246

Item C.1. Identification of investment.

a. Name of issuer (if any).
Money Market Series a series of SL Liquidity Series, LLC
b. LEI (if any) of issuer. (1)
549300I0RQO84VDWQP47
c. Title of the issue or description of the investment.
SL Liquidity Series, LLC, Money Market Series
d. CUSIP (if any).
590204509
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
590204509
Description of other unique identifier.
CUSIP

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
5038011.64000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
5038515.44000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.862079286598

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Short-term investment vehicle (e.g., money market fund, liquidity pool, or other cash management vehicle)
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
i. If Yes, provide the value of the investment representing cash collateral.
5038515.44000000
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 247

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
SAREPTA THERAPEUTICS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960284P9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-62.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-19065.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00326198099

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Sarepta Therapeutics, Inc.
Title of issue.
Sarepta Therapeutics, Inc.
At least one of the following other identifiers:
- CUSIP.
803607100
- ISIN (if CUSIP is not available).
US8036071004
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
135.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-03-31
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
3011.17000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 248

Item C.1. Identification of investment.

a. Name of issuer (if any).
AmerisourceBergen Corp
b. LEI (if any) of issuer. (1)
AI8GXW8LG5WK7E9UD086
c. Title of the issue or description of the investment.
AmerisourceBergen Corp
d. CUSIP (if any).
03073E105
At least one of the following other identifiers:
- ISIN
US03073E1055

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
55773.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
8929815.03000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
1.527872378717

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 249

Item C.1. Identification of investment.

a. Name of issuer (if any).
Rapid Micro Biosystems Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Rapid Micro Biosystems Inc
d. CUSIP (if any).
75340L104
At least one of the following other identifiers:
- ISIN
US75340L1044

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
20561.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
26934.91000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.004608505873

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 250

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
EXACT SCIENCES CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95Z3ST06
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-27.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-2970.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00050816068

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Exact Sciences Corp.
Title of issue.
Exact Sciences Corp.
At least one of the following other identifiers:
- CUSIP.
30063P105
- ISIN (if CUSIP is not available).
US30063P1057
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
72.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
1573.80000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 251

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
AMERISOURCEBERGEN CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z96050LN9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-23.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-7302.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00124944223

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
AmerisourceBergen Corp.
Title of issue.
AmerisourceBergen Corp.
At least one of the following other identifiers:
- CUSIP.
03073E105
- ISIN (if CUSIP is not available).
US03073E1055
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
160.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-1103.07000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 252

Item C.1. Identification of investment.

a. Name of issuer (if any).
Sanofi
b. LEI (if any) of issuer. (1)
549300E9PC51EN656011
c. Title of the issue or description of the investment.
Sanofi
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- ISIN
FR0000120578

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
24587.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
Euro Member Countries
e. Value. (4)
2667166.18000000
f. Exchange rate.
0.92208400
g. Percentage value compared to net assets of the Fund.
0.456346466548

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
FRANCE
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 253

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
INCYTE CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9600DX78
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-102.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-510.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00008725991

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Incyte Corp.
Title of issue.
Incyte Corp.
At least one of the following other identifiers:
- CUSIP.
45337C102
- ISIN (if CUSIP is not available).
US45337C1027
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
82.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
17622.21000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 254

Item C.1. Identification of investment.

a. Name of issuer (if any).
JANE STREET EXECUTION SERVICES, LLC
b. LEI (if any) of issuer. (1)
549300HXJLXCPDWAH070
c. Title of the issue or description of the investment.
RVMD US FLEX
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYCS2JE2
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-35.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-187.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00003208085

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1JANE STREET EXECUTION SERVICES, LLC549300HXJLXCPDWAH070

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
REVOLUTION Medicines, Inc.
Title of issue.
REVOLUTION Medicines, Inc.
At least one of the following other identifiers:
- CUSIP.
76155X100
- ISIN (if CUSIP is not available).
US76155X1000
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
30.10000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
13139.55000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 255

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
IMMUNOCORE HOLDINGS PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95U0NJ02
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-36.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-3060.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00052355949

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Immunocore Holdings PLC
Title of issue.
Immunocore Holdings PLC
At least one of the following other identifiers:
- CUSIP.
45258D105
- ISIN (if CUSIP is not available).
US45258D1054
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
70.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
9924.56000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 256

Item C.1. Identification of investment.

a. Name of issuer (if any).
MORGAN STANLEY & CO. INTERNATIONAL
b. LEI (if any) of issuer. (1)
4PQUHN3JPFGFNF3BB653
c. Title of the issue or description of the investment.
APR23 NOVOB DC C @ 1016.124
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYEKPYN8
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-5000.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
Denmark Krone
e. Value. (4)
-51054.24000000
f. Exchange rate.
6.86935000
g. Percentage value compared to net assets of the Fund.
-0.00873527199

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1MORGAN STANLEY & CO. INTERNATIONAL4PQUHN3JPFGFNF3BB653

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Novo Nordisk A/S
Title of issue.
Novo Nordisk A/S
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
DK0060534915
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
1016.12000000
vi. Exercise Price Currency Code
Denmark Krone
vii. Expiration date.
2023-04-05
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-37676.33000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 257

Item C.1. Identification of investment.

a. Name of issuer (if any).
Prime Medicine Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Prime Medicine Inc
d. CUSIP (if any).
74168J101
At least one of the following other identifiers:
- ISIN
US74168J1016

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
22929.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
282026.70000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.048254169156

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
i. If Yes, provide the value of the securities on loan.
112803.30000000
Schedule of Portfolio Investments Record: 258

Item C.1. Identification of investment.

a. Name of issuer (if any).
Ultragenyx Pharmaceutical Inc
b. LEI (if any) of issuer. (1)
529900EV44GVDN1DCX77
c. Title of the issue or description of the investment.
Ultragenyx Pharmaceutical Inc
d. CUSIP (if any).
90400D108
At least one of the following other identifiers:
- ISIN
US90400D1081

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
6140.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
246214.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.042126692276

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 259

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
REGENERON PHARMACEUTICALS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960YJZ35
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-20.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-86500.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01479996621

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Regeneron Pharmaceuticals, Inc.
Title of issue.
Regeneron Pharmaceuticals, Inc.
At least one of the following other identifiers:
- CUSIP.
75886F107
- ISIN (if CUSIP is not available).
US75886F1075
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
790.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-51119.87000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 260

Item C.1. Identification of investment.

a. Name of issuer (if any).
ARCUTIS BIOTHERAPEUTICS, INC
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
ARCUTIS BIOTHERAPEUTICS, INC
d. CUSIP (if any).
03969K108
At least one of the following other identifiers:
- ISIN
US03969K1088

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
42854.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
471394.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.080654511843

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 261

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MERCK + CO INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z961L0LW9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-210.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-52710.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00901856900

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Merck & Co., Inc.
Title of issue.
Merck & Co., Inc.
At least one of the following other identifiers:
- CUSIP.
58933Y105
- ISIN (if CUSIP is not available).
US58933Y1055
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
108.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-05
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-15793.90000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 262

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
HOLOGIC INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z96065ZP7
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-21.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-4305.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00073657635

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Hologic, Inc.
Title of issue.
Hologic, Inc.
At least one of the following other identifiers:
- CUSIP.
436440101
- ISIN (if CUSIP is not available).
US4364401012
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
80.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-571.85000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 263

Item C.1. Identification of investment.

a. Name of issuer (if any).
Design Therapeutics Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Design Therapeutics Inc
d. CUSIP (if any).
25056L103
At least one of the following other identifiers:
- ISIN
US25056L1035

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
13967.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
80589.59000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.013788707622

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 264

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MEDTRONIC PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z961DSJ91
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-44.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-4444.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00076035895

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Medtronic PLC
Title of issue.
Medtronic PLC
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
IE00BTN1Y115
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
82.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
2101.86000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 265

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
CEREVEL THERAPEUTICS HOLDINGS
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95V08H88
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-31.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-5812.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00099450640

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Cerevel Therapeutics Holdings, Inc.
Title of issue.
Cerevel Therapeutics Holdings, Inc.
At least one of the following other identifiers:
- CUSIP.
15678U128
- ISIN (if CUSIP is not available).
US15678U1280
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
25.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-237.86000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 266

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
BAXTER INTERNATIONAL INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z961KQ7C3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-177.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-40267.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00688968369

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Baxter International, Inc.
Title of issue.
Baxter International, Inc.
At least one of the following other identifiers:
- CUSIP.
071813109
- ISIN (if CUSIP is not available).
US0718131099
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
40.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-05
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-12273.24000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 267

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
REVOLUTION MEDICINES INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9619JTP9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-18.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-1260.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00021558332

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
REVOLUTION Medicines, Inc.
Title of issue.
REVOLUTION Medicines, Inc.
At least one of the following other identifiers:
- CUSIP.
76155X100
- ISIN (if CUSIP is not available).
US76155X1000
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
25.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
852.55000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 268

Item C.1. Identification of investment.

a. Name of issuer (if any).
Arvinas Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Arvinas Inc
d. CUSIP (if any).
04335A105
At least one of the following other identifiers:
- ISIN
US04335A1051

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
15330.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
418815.60000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.071658459314

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 269

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
JOHNSON + JOHNSON
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95U0Z2J2
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-110.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-605.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00010351421

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Johnson & Johnson
Title of issue.
Johnson & Johnson
At least one of the following other identifiers:
- CUSIP.
478160104
- ISIN (if CUSIP is not available).
US4781601046
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
170.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
22392.77000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 270

Item C.1. Identification of investment.

a. Name of issuer (if any).
BlackRock Liquidity Funds
b. LEI (if any) of issuer. (1)
5493007YVNX55LTRQ706
c. Title of the issue or description of the investment.
BlackRock Liquidity Funds: T-Fund, Institutional Shares
d. CUSIP (if any).
09248U718
At least one of the following other identifiers:
- ISIN
US09248U7182

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
20478473.53000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
20478473.53000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
3.503823310972

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Short-term investment vehicle (e.g., money market fund, liquidity pool, or other cash management vehicle)
b. Issuer type. (7)
Registered fund

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 271

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
PFIZER INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960YHEH1
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-275.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-12100.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00207028429

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Pfizer, Inc.
Title of issue.
Pfizer, Inc.
At least one of the following other identifiers:
- CUSIP.
717081103
- ISIN (if CUSIP is not available).
US7170811035
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
42.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
5022.87000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 272

Item C.1. Identification of investment.

a. Name of issuer (if any).
Neurocrine Biosciences Inc
b. LEI (if any) of issuer. (1)
549300FECER0XBN49756
c. Title of the issue or description of the investment.
Neurocrine Biosciences Inc
d. CUSIP (if any).
64125C109
At least one of the following other identifiers:
- ISIN
US64125C1099

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
23254.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
2353769.88000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.402725025482

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 273

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ABBOTT LABORATORIES
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960PN018
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-246.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-2091.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00035776565

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Abbott Laboratories
Title of issue.
Abbott Laboratories
At least one of the following other identifiers:
- CUSIP.
002824100
- ISIN (if CUSIP is not available).
US0028241000
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
107.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-14
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
26962.91000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 274

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
LEGEND BIOTECH CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95V1F5M3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-26.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-6565.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00112325755

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
CAYMAN ISLANDS
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Legend Biotech Corp.
Title of issue.
Legend Biotech Corp.
At least one of the following other identifiers:
- CUSIP.
52490G102
- ISIN (if CUSIP is not available).
US52490G1022
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
55.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
136.88000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 275

Item C.1. Identification of investment.

a. Name of issuer (if any).
HCA Healthcare Inc
b. LEI (if any) of issuer. (1)
529900PH4ZGUH2MNEU89
c. Title of the issue or description of the investment.
HCA Healthcare Inc
d. CUSIP (if any).
40412C101
At least one of the following other identifiers:
- ISIN
US40412C1018

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
14645.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
3861593.60000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.660710460345

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 276

Item C.1. Identification of investment.

a. Name of issuer (if any).
Masimo Corp
b. LEI (if any) of issuer. (1)
549300Q4A8JK0PIYCU29
c. Title of the issue or description of the investment.
Masimo Corp
d. CUSIP (if any).
574795100
At least one of the following other identifiers:
- ISIN
US5747951003

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
8860.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1635024.40000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.279749200951

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
i. If Yes, provide the value of the securities on loan.
608982.00000000
Schedule of Portfolio Investments Record: 277

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ALKERMES PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95UZWM34
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-19.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-2042.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00034946741

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Alkermes PLC
Title of issue.
Alkermes PLC
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
IE00B56GVS15
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
29.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
28.88000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 278

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ELI LILLY + CO
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960YCXL2
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-139.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-148730.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.02544738699

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Eli Lilly & Co.
Title of issue.
Eli Lilly & Co.
At least one of the following other identifiers:
- CUSIP.
532457108
- ISIN (if CUSIP is not available).
US5324571083
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
345.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-28
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-70411.03000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 279

Item C.1. Identification of investment.

a. Name of issuer (if any).
Avantor Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Avantor Inc
d. CUSIP (if any).
05352A100
At least one of the following other identifiers:
- ISIN
US05352A1007

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
78897.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1667882.58000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.285371165736

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 280

Item C.1. Identification of investment.

a. Name of issuer (if any).
McKesson Corp
b. LEI (if any) of issuer. (1)
549300WZWOM80UCFSF54
c. Title of the issue or description of the investment.
McKesson Corp
d. CUSIP (if any).
58155Q103
At least one of the following other identifiers:
- ISIN
US58155Q1031

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
24550.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
8741027.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
1.495571233445

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 281

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
KRYSTAL BIOTECH INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95V1EKL1
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-6.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-1920.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00032850792

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Krystal Biotech, Inc.
Title of issue.
Krystal Biotech, Inc.
At least one of the following other identifiers:
- CUSIP.
501147102
- ISIN (if CUSIP is not available).
US5011471027
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
95.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
397.19000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 282

Item C.1. Identification of investment.

a. Name of issuer (if any).
Humana Inc
b. LEI (if any) of issuer. (1)
529900YLDW34GJAO4J06
c. Title of the issue or description of the investment.
Humana Inc
d. CUSIP (if any).
444859102
At least one of the following other identifiers:
- ISIN
US4448591028

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
9185.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
4458950.10000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.762916888309

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 283

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
DEXCOM INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960PU129
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-99.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-39600.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00677547586

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Dexcom, Inc.
Title of issue.
Dexcom, Inc.
At least one of the following other identifiers:
- CUSIP.
252131107
- ISIN (if CUSIP is not available).
US2521311074
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
125.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
3146.43000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 284

Item C.1. Identification of investment.

a. Name of issuer (if any).
Bausch + Lomb Corp
b. LEI (if any) of issuer. (1)
549300NY6OZM39SO6475
c. Title of the issue or description of the investment.
Bausch + Lomb Corp
d. CUSIP (if any).
071705107
At least one of the following other identifiers:
- ISIN
CA0717051076

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
75830.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1320200.30000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.225883466339

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
CANADA (FEDERAL LEVEL)
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 285

Item C.1. Identification of investment.

a. Name of issuer (if any).
GOLDMAN SACHS INTERNATIONAL
b. LEI (if any) of issuer. (1)
W22LROWP2IHZNBB6K528
c. Title of the issue or description of the investment.
MAY23 AZN LN C @ 114.0833
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYFMS5F6
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-8900.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United Kingdom Pound
e. Value. (4)
-28718.30000000
f. Exchange rate.
0.81063600
g. Percentage value compared to net assets of the Fund.
-0.00491364011

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1GOLDMAN SACHS INTERNATIONALW22LROWP2IHZNBB6K528

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
AstraZeneca PLC
Title of issue.
AstraZeneca PLC
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
GB0009895292
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
114.08330000
vi. Exercise Price Currency Code
United Kingdom Pound
vii. Expiration date.
2023-05-10
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-9931.77000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 286

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
CIGNA GROUP/THE
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9600FZH9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-111.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-5550.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00094959320

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Cigna Group
Title of issue.
Cigna Group
At least one of the following other identifiers:
- CUSIP.
125523100
- ISIN (if CUSIP is not available).
US1255231003
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
305.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-03-31
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
36520.99000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 287

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
REGENERON PHARMACEUTICALS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95Z4VED6
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-21.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-92715.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01586333951

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Regeneron Pharmaceuticals, Inc.
Title of issue.
Regeneron Pharmaceuticals, Inc.
At least one of the following other identifiers:
- CUSIP.
75886F107
- ISIN (if CUSIP is not available).
US75886F1075
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
785.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-33325.79000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 288

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
SAGE THERAPEUTICS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95V2YSJ3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-62.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-8835.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00151164972

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Sage Therapeutics, Inc.
Title of issue.
Sage Therapeutics, Inc.
At least one of the following other identifiers:
- CUSIP.
78667J108
- ISIN (if CUSIP is not available).
US78667J1088
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
47.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
4046.69000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 289

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
THERMO FISHER SCIENTIFIC INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960QVEQ9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-89.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-176220.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.03015086759

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Thermo Fisher Scientific, Inc.
Title of issue.
Thermo Fisher Scientific, Inc.
At least one of the following other identifiers:
- CUSIP.
883556102
- ISIN (if CUSIP is not available).
US8835561023
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
560.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-14
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-49683.41000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 290

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
SAGE THERAPEUTICS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9607XCR6
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-20.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-1050.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00017965276

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Sage Therapeutics, Inc.
Title of issue.
Sage Therapeutics, Inc.
At least one of the following other identifiers:
- CUSIP.
78667J108
- ISIN (if CUSIP is not available).
US78667J1088
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
47.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
4457.66000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 291

Item C.1. Identification of investment.

a. Name of issuer (if any).
Danaher Corp
b. LEI (if any) of issuer. (1)
S4BKK9OTCEWQ3YHPFM11
c. Title of the issue or description of the investment.
Danaher Corp
d. CUSIP (if any).
235851102
At least one of the following other identifiers:
- ISIN
US2358511028

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
77879.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
19628623.16000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
3.358415718317

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 292

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
GILEAD SCIENCES INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z961EA6Z5
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-182.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-41223.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00705316771

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Gilead Sciences, Inc.
Title of issue.
Gilead Sciences, Inc.
At least one of the following other identifiers:
- CUSIP.
375558103
- ISIN (if CUSIP is not available).
US3755581036
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
82.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-19466.13000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 293

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MEDTRONIC PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z961KZX34
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-75.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-7800.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00133456342

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Medtronic PLC
Title of issue.
Medtronic PLC
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
IE00BTN1Y115
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
83.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-05
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
1257.74000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 294

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
IRHYTHM TECHNOLOGIES INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9606DZP0
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-4.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-3220.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00055093515

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
iRhythm Technologies, Inc.
Title of issue.
iRhythm Technologies, Inc.
At least one of the following other identifiers:
- CUSIP.
450056106
- ISIN (if CUSIP is not available).
US4500561067
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
120.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-854.02000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 295

Item C.1. Identification of investment.

a. Name of issuer (if any).
Regeneron Pharmaceuticals Inc
b. LEI (if any) of issuer. (1)
549300RCBFWIRX3HYQ56
c. Title of the issue or description of the investment.
Regeneron Pharmaceuticals Inc
d. CUSIP (if any).
75886F107
At least one of the following other identifiers:
- ISIN
US75886F1075

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
17857.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
14672561.19000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
2.510444045249

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 296

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
INTUITIVE SURGICAL INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960Q2MR2
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-72.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-90000.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01539880877

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Intuitive Surgical, Inc.
Title of issue.
Intuitive Surgical, Inc.
At least one of the following other identifiers:
- CUSIP.
46120E602
- ISIN (if CUSIP is not available).
US46120E6023
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
245.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-14
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-54286.17000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 297

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
IRHYTHM TECHNOLOGIES INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95V13CA8
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-4.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-3640.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00062279626

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
iRhythm Technologies, Inc.
Title of issue.
iRhythm Technologies, Inc.
At least one of the following other identifiers:
- CUSIP.
450056106
- ISIN (if CUSIP is not available).
US4500561067
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
125.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-728.95000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 298

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
WATERS CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95V2SYU4
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-6.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-4170.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00071347814

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Waters Corp.
Title of issue.
Waters Corp.
At least one of the following other identifiers:
- CUSIP.
941848103
- ISIN (if CUSIP is not available).
US9418481035
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
330.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
1236.13000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 299

Item C.1. Identification of investment.

a. Name of issuer (if any).
CureVac NV
b. LEI (if any) of issuer. (1)
724500BUT8GAG9LMYN56
c. Title of the issue or description of the investment.
CureVac NV
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- ISIN
NL0015436031

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
20488.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
142801.36000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.024433009290

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
NETHERLANDS
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
i. If Yes, provide the value of the securities on loan.
57119.15000000
Schedule of Portfolio Investments Record: 300

Item C.1. Identification of investment.

a. Name of issuer (if any).
JANE STREET EXECUTION SERVICES, LLC
b. LEI (if any) of issuer. (1)
549300HN4UKV1E2R3U73
c. Title of the issue or description of the investment.
APR23 EW US C @ 83.52
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYFCHUJ5
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-47.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-8137.67000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00139233804

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1JANE STREET EXECUTION SERVICES, LLC549300HN4UKV1E2R3U73

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Edwards Lifesciences Corp.
Title of issue.
Edwards Lifesciences Corp.
At least one of the following other identifiers:
- CUSIP.
28176E108
- ISIN (if CUSIP is not available).
US28176E1082
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
83.52000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
1580.48000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 301

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
QIAGEN NV
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9607FH09
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-74.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-14800.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00253224855

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
NETHERLANDS
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
QIAGEN NV
Title of issue.
QIAGEN NV
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
NL0012169213
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
50.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-2755.23000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 302

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
UNITEDHEALTH GROUP INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z961D9YQ8
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-75.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-25875.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00442715752

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
UnitedHealth Group, Inc.
Title of issue.
UnitedHealth Group, Inc.
At least one of the following other identifiers:
- CUSIP.
91324P102
- ISIN (if CUSIP is not available).
US91324P1021
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
495.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
26824.24000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 303

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MODERNA INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95U10NG1
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-23.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-632.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00010821940

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Moderna, Inc.
Title of issue.
Moderna, Inc.
At least one of the following other identifiers:
- CUSIP.
60770K107
- ISIN (if CUSIP is not available).
US60770K1079
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
190.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
14271.63000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 304

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
IQVIA HOLDINGS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95V15AE7
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-30.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-14100.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00241248004

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
IQVIA Holdings, Inc.
Title of issue.
IQVIA Holdings, Inc.
At least one of the following other identifiers:
- CUSIP.
46266C105
- ISIN (if CUSIP is not available).
US46266C1053
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
210.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
2332.99000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 305

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
DANAHER CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95XGSKT3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-134.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-32495.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00555982545

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Danaher Corp.
Title of issue.
Danaher Corp.
At least one of the following other identifiers:
- CUSIP.
235851102
- ISIN (if CUSIP is not available).
US2358511028
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
260.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
11799.08000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 306

Item C.1. Identification of investment.

a. Name of issuer (if any).
Glaukos Corp
b. LEI (if any) of issuer. (1)
5299004JA1LHE21M6T14
c. Title of the issue or description of the investment.
Glaukos Corp
d. CUSIP (if any).
377322102
At least one of the following other identifiers:
- ISIN
US3773221029

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
4880.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
244488.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.041831377343

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 307

Item C.1. Identification of investment.

a. Name of issuer (if any).
Decibel Therapeutics Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Decibel Therapeutics Inc
d. CUSIP (if any).
24343R106
At least one of the following other identifiers:
- ISIN
US24343R1068

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
46884.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
141589.68000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.024225693416

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 308

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
COOPER COS INC/THE
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95V0BZE8
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-31.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-52855.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00904337820

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Cooper Cos., Inc.
Title of issue.
Cooper Cos., Inc.
At least one of the following other identifiers:
- CUSIP.
216648402
- ISIN (if CUSIP is not available).
US2166484020
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
370.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-33518.02000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 309

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ALKERMES PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z96052NT0
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-22.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-880.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00015056613

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Alkermes PLC
Title of issue.
Alkermes PLC
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
IE00B56GVS15
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
29.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
2942.87000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 310

Item C.1. Identification of investment.

a. Name of issuer (if any).
Rocket Pharmaceuticals Inc
b. LEI (if any) of issuer. (1)
549300R7VV82YUIN4Y93
c. Title of the issue or description of the investment.
Rocket Pharmaceuticals Inc
d. CUSIP (if any).
77313F106
At least one of the following other identifiers:
- ISIN
US77313F1066

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
17213.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
294858.69000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.050449695381

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 311

Item C.1. Identification of investment.

a. Name of issuer (if any).
Mettler-Toledo International Inc
b. LEI (if any) of issuer. (1)
5493000BD5GJNUDIUG10
c. Title of the issue or description of the investment.
Mettler-Toledo International Inc
d. CUSIP (if any).
592688105
At least one of the following other identifiers:
- ISIN
US5926881054

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
1055.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1614371.55000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.276215542197

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 312

Item C.1. Identification of investment.

a. Name of issuer (if any).
Afferent Pharmaceuticals, Inc.
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Afferent Pharmaceuticals, Inc.
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRSUB0VG2
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
190160.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
150226.40000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.025703417858

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-preferred
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 313

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ELEVANCE HEALTH INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960PVAJ0
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-34.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-7225.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00123618214

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Elevance Health, Inc.
Title of issue.
Elevance Health, Inc.
At least one of the following other identifiers:
- CUSIP.
036752103
- ISIN (if CUSIP is not available).
US0367521038
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
480.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-14
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
16011.84000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 314

Item C.1. Identification of investment.

a. Name of issuer (if any).
Encompass Health Corp
b. LEI (if any) of issuer. (1)
549300FVRPM9DRQZRG64
c. Title of the issue or description of the investment.
Encompass Health Corp
d. CUSIP (if any).
29261A100
At least one of the following other identifiers:
- ISIN
US29261A1007

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
15684.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
848504.40000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.145177300047

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 315

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
SAREPTA THERAPEUTICS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95TP4158
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-9.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-1665.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00028487796

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Sarepta Therapeutics, Inc.
Title of issue.
Sarepta Therapeutics, Inc.
At least one of the following other identifiers:
- CUSIP.
803607100
- ISIN (if CUSIP is not available).
US8036071004
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
150.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
5303.70000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 316

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
BRISTOL-MYERS SQUIBB CO
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960G5HT8
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-74.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-1739.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00029753920

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Bristol-Myers Squibb Co.
Title of issue.
Bristol-Myers Squibb Co.
At least one of the following other identifiers:
- CUSIP.
110122108
- ISIN (if CUSIP is not available).
US1101221083
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
70.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-06
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
9258.46000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 317

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
PROTHENA CORP PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9619GXL9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-33.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-5445.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00093162793

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Prothena Corp. PLC
Title of issue.
Prothena Corp. PLC
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
IE00B91XRN20
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
55.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
4121.16000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 318

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
VERTEX PHARMACEUTICALS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z960R5T14
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-40.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-67600.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01156621637

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Vertex Pharmaceuticals, Inc.
Title of issue.
Vertex Pharmaceuticals, Inc.
At least one of the following other identifiers:
- CUSIP.
92532F100
- ISIN (if CUSIP is not available).
US92532F1003
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
300.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-14
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-42689.36000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 319

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
EDWARDS LIFESCIENCES CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95V0R8U7
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-42.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-13230.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00226362489

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Edwards Lifesciences Corp.
Title of issue.
Edwards Lifesciences Corp.
At least one of the following other identifiers:
- CUSIP.
28176E108
- ISIN (if CUSIP is not available).
US28176E1082
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
85.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-2461.21000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 320

Item C.1. Identification of investment.

a. Name of issuer (if any).
Alkermes PLC
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Alkermes PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- ISIN
IE00B56GVS15

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
32331.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
911410.89000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.155940466831

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 321

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
QIAGEN NV
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95V24FE4
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-43.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-2902.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00049661158

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
NETHERLANDS
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
QIAGEN NV
Title of issue.
QIAGEN NV
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
NL0012169213
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
50.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
860.78000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 322

Item C.1. Identification of investment.

a. Name of issuer (if any).
Merck & Co Inc
b. LEI (if any) of issuer. (1)
4YV9Y5M8S0BRK1RP0397
c. Title of the issue or description of the investment.
Merck & Co Inc
d. CUSIP (if any).
58933Y105
At least one of the following other identifiers:
- ISIN
US58933Y1055

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
236240.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
25133573.60000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
4.300301042394

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 323

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
INSULET CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9619CX95
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-12.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-11160.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00190945228

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Insulet Corp.
Title of issue.
Insulet Corp.
At least one of the following other identifiers:
- CUSIP.
45784P101
- ISIN (if CUSIP is not available).
US45784P1012
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
340.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-19
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-718.53000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 324

Item C.1. Identification of investment.

a. Name of issuer (if any).
Cooper Cos Inc/The
b. LEI (if any) of issuer. (1)
QJKMVPIGLH7530PCUE20
c. Title of the issue or description of the investment.
Cooper Cos Inc/The
d. CUSIP (if any).
216648402
At least one of the following other identifiers:
- ISIN
US2166484020

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
12951.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
4835385.36000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.827324161494

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
i. If Yes, provide the value of the securities on loan.
1194752.00000000
Schedule of Portfolio Investments Record: 325

Item C.1. Identification of investment.

a. Name of issuer (if any).
Quest Diagnostics Inc
b. LEI (if any) of issuer. (1)
8MCWUBXQ0WE04KMXBX50
c. Title of the issue or description of the investment.
Quest Diagnostics Inc
d. CUSIP (if any).
74834L100
At least one of the following other identifiers:
- ISIN
US74834L1008

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
40564.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
5738994.72000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.981929803118

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 326

Item C.1. Identification of investment.

a. Name of issuer (if any).
STERIS PLC
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
STERIS PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- ISIN
IE00BFY8C754

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
9590.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1834375.20000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.313857699276

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 327

Item C.1. Identification of investment.

a. Name of issuer (if any).
Neurogene, Inc. Series B
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Neurogene, Inc. Series B
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRWBE0GQ1
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
106790.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
260567.60000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.044582562739

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 328

Item C.1. Identification of investment.

a. Name of issuer (if any).
West Pharmaceutical Services Inc
b. LEI (if any) of issuer. (1)
5493007NKRGM1RJQ1P16
c. Title of the issue or description of the investment.
West Pharmaceutical Services Inc
d. CUSIP (if any).
955306105
At least one of the following other identifiers:
- ISIN
US9553061055

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
15420.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
5342567.40000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.914101930944

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 329

Item C.1. Identification of investment.

a. Name of issuer (if any).
PTC Therapeutics Inc
b. LEI (if any) of issuer. (1)
549300UJLWOIWFDGB318
c. Title of the issue or description of the investment.
PTC Therapeutics Inc
d. CUSIP (if any).
69366J200
At least one of the following other identifiers:
- ISIN
US69366J2006

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
6385.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
309289.40000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.052918759201

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 330

Item C.1. Identification of investment.

a. Name of issuer (if any).
UBS AG
b. LEI (if any) of issuer. (1)
BFM8T61CT2L1QCEMIK50
c. Title of the issue or description of the investment.
APR23 NOVOB DC C @ 1026.8026
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYEXYH38
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-5000.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
Denmark Krone
e. Value. (4)
-49310.09000000
f. Exchange rate.
6.86935000
g. Percentage value compared to net assets of the Fund.
-0.00843685163

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1UBS AGBFM8T61CT2L1QCEMIK50

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Novo Nordisk A/S
Title of issue.
Novo Nordisk A/S
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
DK0060534915
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
1026.80260000
vi. Exercise Price Currency Code
Denmark Krone
vii. Expiration date.
2023-04-26
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-35643.70000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 331

Item C.1. Identification of investment.

a. Name of issuer (if any).
Waters Corp
b. LEI (if any) of issuer. (1)
5T547R1474YC9HOD8Q74
c. Title of the issue or description of the investment.
Waters Corp
d. CUSIP (if any).
941848103
At least one of the following other identifiers:
- ISIN
US9418481035

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
12225.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
3785226.75000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.647644254564

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 332

Item C.1. Identification of investment.

a. Name of issuer (if any).
Eli Lilly & Co
b. LEI (if any) of issuer. (1)
FRDRIPF3EKNDJ2CQJL29
c. Title of the issue or description of the investment.
Eli Lilly & Co
d. CUSIP (if any).
532457108
At least one of the following other identifiers:
- ISIN
US5324571083

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
98033.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
33666492.86000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
5.760265398138

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 333

Item C.1. Identification of investment.

a. Name of issuer (if any).
CARBON HEALTH TECHNOLOGIES INC
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
CARBON HEALTH TECHNOLOGIES INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYDATTD1
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
89892.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1066119.12000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.182410716280

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 334

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ALNYLAM PHARMACEUTICALS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9604Z9M9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-16.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-3200.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00054751320

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Alnylam Pharmaceuticals, Inc.
Title of issue.
Alnylam Pharmaceuticals, Inc.
At least one of the following other identifiers:
- CUSIP.
02043Q107
- ISIN (if CUSIP is not available).
US02043Q1076
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
250.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
8855.46000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 335

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
JOHNSON + JOHNSON
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z961KY9V2
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-96.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-20688.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00353967284

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Johnson & Johnson
Title of issue.
Johnson & Johnson
At least one of the following other identifiers:
- CUSIP.
478160104
- ISIN (if CUSIP is not available).
US4781601046
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
160.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-05
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-7373.10000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 336

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
STERIS PLC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9607Q540
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-5.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-4550.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00077849533

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
IRELAND
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
STERIS PLC
Title of issue.
STERIS PLC
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
IE00BFY8C754
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
185.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-3361.16000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 337

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
GLAUKOS CORP
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95U2UU84
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-9.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-1102.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00018863540

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Glaukos Corp.
Title of issue.
Glaukos Corp.
At least one of the following other identifiers:
- CUSIP.
377322102
- ISIN (if CUSIP is not available).
US3773221029
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
52.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
1648.19000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 338

Item C.1. Identification of investment.

a. Name of issuer (if any).
Catalent Inc
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Catalent Inc
d. CUSIP (if any).
148806102
At least one of the following other identifiers:
- ISIN
US1488061029

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
20045.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
1317156.95000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.225362755620

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 339

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
MERCK + CO INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z95U10D56
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-209.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-2194.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00037547428

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Merck & Co., Inc.
Title of issue.
Merck & Co., Inc.
At least one of the following other identifiers:
- CUSIP.
58933Y105
- ISIN (if CUSIP is not available).
US58933Y1055
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
115.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
29525.37000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 340

Item C.1. Identification of investment.

a. Name of issuer (if any).
IDEXX Laboratories Inc
b. LEI (if any) of issuer. (1)
OGMTXK0LUU1HKV2P0J84
c. Title of the issue or description of the investment.
IDEXX Laboratories Inc
d. CUSIP (if any).
45168D104
At least one of the following other identifiers:
- ISIN
US45168D1046

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
7185.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
3593074.80000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.614767464179

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 341

Item C.1. Identification of investment.

a. Name of issuer (if any).
Hologic Inc
b. LEI (if any) of issuer. (1)
549300DYP6F5ZJL0LB74
c. Title of the issue or description of the investment.
Hologic Inc
d. CUSIP (if any).
436440101
At least one of the following other identifiers:
- ISIN
US4364401012

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
10990.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
886893.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.151745507944

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 342

Item C.1. Identification of investment.

a. Name of issuer (if any).
Baxter International Inc
b. LEI (if any) of issuer. (1)
J5OIVXX3P24RJRW5CK77
c. Title of the issue or description of the investment.
Baxter International Inc
d. CUSIP (if any).
071813109
At least one of the following other identifiers:
- ISIN
US0718131099

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
111827.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
4535703.12000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.776049166956

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 343

Item C.1. Identification of investment.

a. Name of issuer (if any).
Bristol-Myers Squibb Co
b. LEI (if any) of issuer. (1)
HLYYNH7UQUORYSJQCN42
c. Title of the issue or description of the investment.
Bristol-Myers Squibb Co
d. CUSIP (if any).
110122108
At least one of the following other identifiers:
- ISIN
US1101221083

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
39106.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
2710436.86000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.463749987960

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 344

Item C.1. Identification of investment.

a. Name of issuer (if any).
Insitro, Series C
b. LEI (if any) of issuer. (1)
N/A
c. Title of the issue or description of the investment.
Insitro, Series C
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRWH9E7P6
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
30616.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
356064.08000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
0.060921807569

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 345

Item C.1. Identification of investment.

a. Name of issuer (if any).
NOMURA SECURITIES INTERNATIONAL INC
b. LEI (if any) of issuer. (1)
OXTKY6Q8X53C9ILVV871
c. Title of the issue or description of the investment.
MAY23 BMRN US C @ 96.5
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYF2F6M0
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-80.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-40646.80000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00695458111

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1NOMURA SECURITIES INTERNATIONAL INCOXTKY6Q8X53C9ILVV871

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
BioMarin Pharmaceutical, Inc.
Title of issue.
BioMarin Pharmaceutical, Inc.
At least one of the following other identifiers:
- CUSIP.
09061G101
- ISIN (if CUSIP is not available).
US09061G1013
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
96.50000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-12
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-19545.30000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 346

Item C.1. Identification of investment.

a. Name of issuer (if any).
UBS AG
b. LEI (if any) of issuer. (1)
BFM8T61CT2L1QCEMIK50
c. Title of the issue or description of the investment.
APR23 BLCO US C @ 17.25
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYDPCTB6
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-8000.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-3382.24000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00057869407

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1UBS AGBFM8T61CT2L1QCEMIK50

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Bausch & Lomb Corp.
Title of issue.
Bausch & Lomb Corp.
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
CA0717051076
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
17.25000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-05
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
6702.55000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 347

Item C.1. Identification of investment.

a. Name of issuer (if any).
JP MORGAN CHASE BANK
b. LEI (if any) of issuer. (1)
7H6GLXDRUGQFU57RNE97
c. Title of the issue or description of the investment.
MAY23 ALKS US C @ 27.308
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYF2QZR3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-5900.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-10821.13000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00185147235

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1JP MORGAN CHASE BANK7H6GLXDRUGQFU57RNE97

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Alkermes PLC
Title of issue.
Alkermes PLC
At least one of the following other identifiers:
- ISIN (if CUSIP is not available).
IE00B56GVS15
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
1.00000000
v. Exercise price or rate.
27.30800000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-08
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-4624.36000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 348

Item C.1. Identification of investment.

a. Name of issuer (if any).
Gilead Sciences Inc
b. LEI (if any) of issuer. (1)
549300WTZWR07K8MNV44
c. Title of the issue or description of the investment.
Gilead Sciences Inc
d. CUSIP (if any).
375558103
At least one of the following other identifiers:
- ISIN
US3755581036

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
172670.00000000
b. Units
Number of shares
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
14326429.90000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
2.451221716945

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Equity-common
b. Issuer type. (7)
Corporate

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

N/A

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 349

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ABBOTT LABORATORIES
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z961KPKP1
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-231.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-69300.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.01185708276

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Abbott Laboratories
Title of issue.
Abbott Laboratories
At least one of the following other identifiers:
- CUSIP.
002824100
- ISIN (if CUSIP is not available).
US0028241000
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
101.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-05-05
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-21074.30000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 350

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
10X GENOMICS INC
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9607LUR2
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-15.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-10425.00000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00178369535

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
10X Genomics, Inc.
Title of issue.
10X Genomics, Inc.
At least one of the following other identifiers:
- CUSIP.
88025U109
- ISIN (if CUSIP is not available).
US88025U1097
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
50.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-858.66000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 351

Item C.1. Identification of investment.

a. Name of issuer (if any).
Options Clearing Corp.
b. LEI (if any) of issuer. (1)
549300CII6SLYGKNHA04
c. Title of the issue or description of the investment.
ARGENX SE
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
Z9608MJX9
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-27.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-10057.50000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00172081688

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
NETHERLANDS
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1Options Clearing Corp.549300CII6SLYGKNHA04

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Argenx SE
Title of issue.
Argenx SE
At least one of the following other identifiers:
- CUSIP.
04016X101
- ISIN (if CUSIP is not available).
US04016X1019
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
400.00000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
19029.84000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No
Schedule of Portfolio Investments Record: 352

Item C.1. Identification of investment.

a. Name of issuer (if any).
NOMURA SECURITIES INTERNATIONAL INC
b. LEI (if any) of issuer. (1)
OXTKY6Q8X53C9ILVV871
c. Title of the issue or description of the investment.
BSX US FLEX
d. CUSIP (if any).
000000000
At least one of the following other identifiers:
- Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used
BRYDUH9X3
Description of other unique identifier.
BlackRock Identifier

Item C.2. Amount of each investment.

Balance. (2)
a. Balance
-111.00000000
b. Units
Number of contracts
c. Description of other units.
d. Currency. (3)
United States Dollar
e. Value. (4)
-30034.38000000
f. Exchange rate.
g. Percentage value compared to net assets of the Fund.
-0.00513881860

Item C.3. Payoff profile.

a. Payoff profile. (5) Long Short N/A

Item C.4. Asset and issuer type.

a. Asset type. (6)
Derivative-equity
b. Issuer type. (7)

Item C.5. Country of investment or issuer.

a. ISO country code. (8)
UNITED STATES OF AMERICA
b. Investment ISO country code. (9)

Item C.6. Is the investment a Restricted Security?

a. Is the investment a Restricted Security? Yes No

Item C.7. Liquidity classification information.

a. Liquidity classification information. (10)
Category.
N/A

Item C.8. Fair value level.

a. Level within the fair value hierarchy (12) 1 2 3 N/A

Item C.9. Debt securities.

N/A

Item C.10. Repurchase and reverse repurchase agreements.

N/A

Item C.11. Derivatives.

a. Type of derivative instrument (21)
Option
b. Counterparty.
i. Provide the name and LEI (if any) of counterparty (including a central counterparty).

Counterparty Info RecordName of counterpartyLEI (if any) of counterparty
#1NOMURA SECURITIES INTERNATIONAL INCOXTKY6Q8X53C9ILVV871

ii. Type, selected from among the following (put, call). Respond call for warrants. Put Call
iii. Payoff profile, selected from among the following (written, purchased). Respond purchased for warrants. Written Purchased
3. The reference instrument is neither a derivative or an index (28)
Name of issuer.
Boston Scientific Corp.
Title of issue.
Boston Scientific Corp.
At least one of the following other identifiers:
- CUSIP.
101137107
- ISIN (if CUSIP is not available).
US1011371077
iv. Number of shares or principal amount of underlying reference instrument per contract.
Number of shares.
100.00000000
v. Exercise price or rate.
47.74000000
vi. Exercise Price Currency Code
United States Dollar
vii. Expiration date.
2023-04-21
viii. Delta.
XXXX
ix. Unrealized appreciation or depreciation. (24)
-12979.52000000

Item C.12. Securities lending.

a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? Yes No
b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? Yes No
c. Is any portion of this investment on loan by the Fund? Yes No

NPORT-P: Part E: Explanatory Notes (if any)

The Fund may provide any information it believes would be helpful in understanding the information reported in response to any Item of this Form. The Fund may also explain any assumptions that it made in responding to any Item of this Form. To the extent responses relate to a particular Item, provide the Item number(s), as applicable.

Explanatory Note RecordNote ItemExplanatory Notes
#1B.5.aMonthly returns presented in Item B.5(a) have been calculated without deducting any applicable sales loads or redemption fees.

NPORT-P: Additional notes

IdentifierNote
(1) LEI (if any) of issuer. In the case of a holding in a fund that is a series of a series trust, report the LEI of the series.
(2) Balance. Indicate whether amount is expressed in number of shares, principal amount, or other units. For derivatives contracts, as applicable, provide the number of contracts.
(3) Currency. Indicate the currency in which the investment is denominated.
(4) Value. Report values in U.S. dollars. If currency of investment is not denominated in U.S. dollars, provide the exchange rate used to calculate value.
(5) Indicate payoff profile among the following categories (long, short, N/A). For derivatives, respond N/A to this Item and respond to the relevant payoff profile question in Item [C/D].11.
(6) Asset type (short-term investment vehicle (e.g., money market fund, liquidity pool, or other cash management vehicle), repurchase agreement, equity-common, equity-preferred, debt, derivative-commodity, derivative-credit, derivative-equity, derivative-foreign exchange, derivative-interest rate, derivatives-other, structured note, loan, ABS-mortgage backed security, ABS-asset backed commercial paper, ABS-collateralized bond/debt obligation, ABS-other, commodity, real estate, other). If “other” provide a brief description.
(7) Issuer type (corporate, U.S. Treasury, U.S. government agency, U.S. government sponsored entity, municipal, non-U.S. sovereign, private fund, registered fund, other). If “other” provide a brief description.
(8) Report the ISO country code that corresponds to the country where the issuer is organized.
(9) If different from the country where the issuer is organized, also report the ISO country code that corresponds to the country of investment or issuer based on the concentrations of the risk and economic exposure of the investments.
(10) Liquidity classification information. For portfolio investments of open-end management investment companies, provide the liquidity classification(s) for each portfolio investment among the following categories as specified in rule 22e-4 [17 CFR 270.22e-4]: Highly Liquid Investments, Moderately Liquid Investments, Less Liquid Investments, Illiquid Investments. For portfolio investments with multiple liquidity classifications, indicate the percentage amount attributable to each classification.
(11) Funds may choose to indicate the percentage amount of a holding attributable to multiple classification categories only in the following circumstances:
(1) if portions of the position have differing liquidity features that justify treating the portions separately;
(2) if a fund has multiple sub-advisers with differing liquidity views; or
(3) if the fund chooses to classify the position through evaluation of how long it would take to liquidate the entire position (rather than basing it on the sizes it would reasonably anticipated trading).
In (1) and (2), a fund would classify using the reasonably anticipated trade size for each portion of the position.
(12) Indicate the level within the fair value hierarchy in which the fair value measurements fall pursuant to U.S. Generally Accepted Accounting Principles 7 (ASC 820, Fair Value Measurement). [1/2/3] Report "N/A" if the investment does not have a level associated with it (i.e., net asset value used as the practical expedient).
(13) Select the category that most closely reflects the coupon type among the following (fixed, floating, variable, none).
(14) Are there any interest payments in arrears or have any coupon payments been legally deferred by the issuer? [Y/N]
(15) Enter "N" if the interest may be paid in kind but is not actually paid in kind or if the Fund has the option of electing in-kind payment and has elected to be paid in-kind.
(16) Description of the reference instrument, including the name of issuer, title of issue, and currency in which denominated, as well as CUSIP of reference instrument, ISIN (if CUSIP is not available), ticker (if CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).
If other identifier provided, indicate the type of identifier used.
(17) Conversion ratio per US$1000 notional, or, if bond currency is not in U.S. dollars, per 1000 units of the relevant currency, indicating the relevant currency. If there is more than one conversion ratio, provide each conversion ratio.
(18) Select the category that reflects the transaction (repurchase, reverse repurchase). Select "repurchase agreement" if the Fund is the cash lender and receives collateral. Select "reverse repurchase agreement" if the Fund is the cash borrower and posts collateral.
(19) If multiple securities of an issuer are subject to the repurchase agreement, those securities may be aggregated.
(20) Category of investments that most closely represents the collateral, selected from among the following (asset-backed securities; agency collateralized mortgage obligations; agency debentures and agency strips; agency mortgage-backed securities; private label collateralized mortgage obligations; corporate debt securities; equities; money market; U.S. Treasuries (including strips); other instrument). If "other instrument", include a brief description, including, if applicable, whether it is a collateralized debt obligation, municipal debt, whole loan, or international debt
(21) Type of derivative instrument that most closely represents the investment, selected from among the following (forward, future, option, swaption, swap (including but not limited to total return swaps, credit default swaps, and interest rate swaps), warrant, other).
(22) In the case of a holding in a fund that is a series of a series trust, report the LEI of the series.
(23) Description and terms of payments necessary for a user of financial information to understand the terms of payments to be paid and received, including, as applicable, description of the reference instrument, obligation, or index, financing rate, floating coupon rate, fixed coupon rate, and payment frequency.
(24) Depreciation shall be reported as a negative number.
(25) If the reference instrument is a derivative, indicate the category of derivative from among the categories listed in sub-Item C.11.a. and provide all information required to be reported on this Form for that category.
(26) If the reference instrument is an index or custom basket, and if the index’s or custom basket’s components are publicly available on a website and are updated on that website no less frequently than quarterly, identify the index and provide the index identifier, if any. If the index’s or custom basket’s components are not publicly available in that manner, and the notional amount of the derivative represents 1% or less of the net asset value of the Fund, provide a narrative description of the index. If the index’s or custom basket’s components are not publicly available in that manner, and the notional amount of the derivative represents more than 5% of the net asset value of the Fund, provide the (i) name, (ii) identifier, (iii) number of shares or notional amount or contract value as of the trade date (all of which would be reported as negative for short positions), and (iv) value of every component in the index or custom basket. The identifier shall include CUSIP of the index’s or custom basket’s components, ISIN (if CUSIP is not available), ticker (if CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available). If other identifier provided, indicate the type of identifier used.

If the index’s or custom basket’s components are not publicly available in that manner, and the notional amount of the derivative represents greater than 1%, but 5% or less, of the net asset value of the Fund, Funds shall report the required component information described above, but may limit reporting to the (i) 50 largest components in the index and (ii) any other components where the notional value for that components is over 1% of the notional value of the index or custom basket.
An index or custom basket, where the components are publicly available on a website and are updated on that website no less frequently than quarterly.
(27) If the index’s or custom basket’s components are not publicly available in that manner, and the notional amount of the derivative represents 1% or less of the net asset value of the Fund, provide a narrative description of the index.
(28) If the reference instrument is neither a derivative or an index, the description of the reference instrument shall include the name of issuer and title of issue, as well as CUSIP of the reference instrument, ISIN (if CUSIP is not available), ticker if (CUSIP and ISIN are not available), or other identifier (if CUSIP, ISIN, and ticker are not available).

NPORT-P: Signatures

The Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Registrant:
BlackRock Health Sciences Trust
By (Signature):
Chuck Pulsfort
Name:
Chuck Pulsfort
Title:
Assistant Treasurer
Date:
2023-05-01


Documents

Grafico Azioni BlackRock Health Sciences (NYSE:BME)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di BlackRock Health Sciences
Grafico Azioni BlackRock Health Sciences (NYSE:BME)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di BlackRock Health Sciences